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Abstract 
CK2 is a ubiquitously expressed and constitutively active serine/threonine protein 
kinase that is implicated in many cellular functions. Previous studies have indicated that 
the generation of mutants that are less sensitive to inhibition can be advantageous when 
studying protein kinases. Importantly, studies have demonstrated that mutants of CK2 
rendered less sensitive to inhibition are attainable. To extend these observations, mutants 
of CK2α were designed and evaluated to test their effect on the inhibition of CK2 by CX-
4945 using in vitro enzymatic assays followed by the development of inducible cell lines. 
CX-4945 is a CK2 inhibitor that has demonstrated anti-tumor activity and has recently 
been extended into clinical trails phase II. It was demonstrated that a CK2α triple mutant 
(V66A/H160D/I174A) led to a reduction in the inhibition of CK2 by CX-4945. 
Generation of CK2 inhibitor-refractory mutants will provide valuable insight regarding 
the precise functions of CK2 as well as its inhibition.  
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1 – Introduction  
1.1 – Introduction to protein kinases 
It has long been recognized that one of the most important mechanisms of regulation 
of dynamic cellular processes is the reversible phosphorylation of proteins mediated by 
protein kinases1,2. Protein kinases are enzymes, which catalyze the transfer of a 
phosphoryl group, specifically from the gamma phosphate of ATP or in some cases GTP, 
to the hydroxyl group of serine, threonine, or tyrosine residues on a recipient substrate2. 
Importantly, the phosphorylation of substrates often results in a downstream activation 
cascade promoting the execution of key cellular process including but not limited to 
survival, proliferation, and apoptosis. To further highlight the significance of protein 
kinases in cells, there have been 518 genes encoding kinases that have been identified, 
representing approximately 1.7% of the entire human genome3,4.  
To elucidate the mechanisms that regulate protein kinases, many structural 
investigations have been employed to understand the general features of these enzymes, 
providing insight into their activation, inhibition, and substrate recognition2,5. Through 
key studies utilizing PKA and Cdk2, a major distinguishing feature of protein kinases is 
the conformational distinctions existing between the active vs. inactive forms of 
kinases6,7. Switching between the two states is triggered by specific signaling events, 
transduced via kinase regulatory domains that provide a means of activation or 
inactivation. With respects to substrate recognition, it has been determined that many 
protein kinases require certain residues located proximal to the sites that they recognize 
on substrates in order to achieve selectivity and specificity towards a particular substrate8. 
Typically, it is less well-ordered regions exposed to the surface of the protein substrate 
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that are targeted by protein kinases. This enables protein kinases to adopt an extended 
conformation and promote the localization of those residues that achieve specificity8,9.  
As a result of the features of protein kinases and the vast number of cellular 
functions in which they may coordinate, their aberrant expression and regulation can 
have catastrophic effects on the fate of a living cell. Second only to G-protein coupled 
receptors, protein kinases are emerging as one of the most popular drug targets when 
devising therapeutic strategies, since over 400 human diseases have been directly or 
indirectly associated with protein kinases10. As an example of a successful targeted 
therapy towards a protein kinase however, was the development of the drug Imatinib 
(Gleevec)11–14. This clinical compound serves to target the Bcr-Abl fusion receptor 
tyrosine kinase that is aberrantly expressed and constitutively active in many tumors, and 
most noticeably responsible for the development of chronic myelogenous leukemia 
(CML)15. By binding to the kinase in an ATP-competitive manner, Imatinib prevents 
ATP from gaining access to the catalytic site of Bcr-Abl, which renders the kinases 
inactive. This gives rise to growth inhibition and cell death through their apoptotic 
machinery. In addition to the production of this ATP-competitive compound, another 
therapeutic strategy has been the development of a chimeric monoclonal antibody, 
cetuximab, for the treatment of colorectal cancer was also produced. This antibody 
successfully binds to EGFR and competes for its natural ligand, EGF, as opposed to 
competing with the co- substrate, ATP16. 
One class of protein kinases gaining attention in the field of targeted therapy are 
serine/threonine protein kinases (STK’s), as many alterations have been recently reported 
in a wide variety of human cancers17. In particular, STK’s play a dramatic role in cellular 
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homeostasis through their ability to regulate transcriptional factors, cell cycle regulators, 
and an enormous number of cytoplasmic and nuclear proteins18. Therefore, it is 
undoubtedly recognized that perturbations in signaling via STK’s may play a paramount 
role in malignant transformation. Recent efforts to identify alterations in protein kinase 
expression in various tumor samples have strongly implicated CK2 in a variety of human 
cancers19,20. Accordingly, the work described in this thesis has been concentrated on 
elucidating the precise functions it may orchestrate within cells, as well as evaluating its 
potential as a viable therapeutic target.   
 
1.2 – Protein kinase CK2 
Originally described by Burnett and Kennedy in 195421, protein kinase CK2 is a 
ubiquitously expressed and constitutively active protein serine/threonine kinase within 
eukaryotic cells. Protein kinase CK2 has been distinguished for its unique ability to 
phosphorylate its target substrates specifically at serine or threonine residues located 
proximal to acidic clusters21,22. Work by Pinna and colleagues have identified a minimal 
consensus sequence of S/T-X-X-D/E, with position n+3 being a major determinant for 
phosphorylation22. Studies investigating the interactome have identified over 100 
interactors of CK2, with a large majority of these being nucleic acid synthesis proteins, as 
well as cellular communication and signal transduction proteins23. In terms of structure, 
CK2 is composed of two catalytic subunits (CK2α and CK2α’), as well as a regulatory 
subunit (CK2β), and exists in cells primarily in the form of a holoenzyme (Figure 1) 
(α2β2, α’2β2, or αα’β2) although the existence of the catalytic subunits in the absence of 
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the regulatory subunit have also been observed24,25. It should be noted that the relative 
abundance of these isoforms within cells currently remains poorly characterized.  
To date, typical phosphorylation assays have been limited in their ability to 
discriminate between the two catalytic isoforms of CK2 and therefore it cannot be 
concluded which form of CK2 is responsible for its activity in particular cellular 
processes26. What is interesting is that CK2α and CK2α’ only exhibit differences in their 
C-termini27. This indicates the potential for functional compensation and specialization 
between the two subunits27. Evidence in support of this resulted from the development of 
tetracycline regulated stable cells lines expressing catalytically inactive forms of CK2α 
and CK2α’28. It was observed that a dramatic reduction in proliferation was detected 
when expressing catalytically inactive forms of CK2α’, although this was not achieved 
with the expression of catalytic inactive CK2α28. To strengthen this, knockout mice 
models with targeted disruption of either CK2α and CK2β resulted in embryonic 
lethality, whereas knockouts of CK2α’ resulted in viable, although sterile mice29. In 
addition, distinction between the two isoforms has also been observed when investigating 
isoform-specific binding partners of CK2α and CK2α’ using a yeast two-hybrid 
approach30. Although evidence continues to grow, casting light onto CK2 specific 
interactions and additional roles within the multitude of cellular processes, much remains 
to be investigated to provide a thorough understanding of the functional specialization 
that may exist between CK2α and CK2α’.  
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Figure 1. Crystal structure of the CK2α holoenzyme  
Using PyMol, the co-ordinates (PDB identification number 3PE1) from the high-
resolution crystal structure of the CK2 tetramer31 were used to generate a ribbon diagram 
representing the CK2α holoenzyme. The CK2α subunit bearing the non-hydrolysable 
ATP analogue adenosine 5’-[β,γ-imido] triphosphate (AMPPNP - red) within its ATP 
binding site is depicted in green. The other CK2α subunit is illustrated in yellow. It is 
worth noting that the AMPPNP analogue only binds to one catalytic subunit, however the 
impact of this observation still remains poorly understood27. The regulatory subunits, 
CK2β, are illustrated in blue and purple.  
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As we continue to advance our understanding of CK2 and its potential to maintain 
cellular homeostasis, one important aspect that has remained challenging to elucidate is 
the regulation of protein kinase CK2. For example, in the early 1990’s, scientists 
evaluated different stimuli for their ability to modulate CK2, although no conclusive 
insights into the mechanisms behind CK2 regulation were identified32. Since then, many 
opposing views have been proposed including the suggestion that CK2 is indeed 
physiologically regulated, potentially by means of regulated CK2 assembly into 
tetrameric complexes24. As it is well known, cyclin-dependent kinases (CDK’s) require 
the presence of cyclins to initiate their catalytic activity within cells33, and from this 
many similarities have been developed between cyclins and the regulatory CK2β subunit. 
Through sequence analysis, it has been identified that CK2β contains a destruction box 
that can be subjected to ubiquitinylation, which permits degradation of CK2β via the 
proteasomal pathway34. Although CK2 levels do not change to the same extent as CDK’s 
during the cell cycle, this observation reflects the tendency of CK2 expression to oscillate 
throughout the cell cycle, again reminiscent to cyclins. In the end, more work must be 
performed in order to provide additional insight into the regulation of CK2, as much still 
remains unknown. 
 
1.3 – Cellular functions of protein kinase CK2 
Both exciting and at times puzzling is the increasing literature on the multitude of 
potential CK2 substrates. As a result, these studies have provided insight into the broad 
array of cellular functions that may involve CK2. Consequently, it seems impractical to 
touch on all aspects of CK2 and its role within cells, and so the following will highlight 
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only the roles of CK2 in the context of cellular proliferation and survival as these roles 
are more established. 
 
1.3.1 – CK2 and a role in proliferation  
One of the better-established roles of CK2 in eukaryotic systems is its ability to 
monitor and maintain the cell cycle to ensure the proper production of daughter cells. 
In fact, CK2 has been implicated in all stages of the cell cycle35. For example, antisense 
oligonucleotides and inhibitors directed against CK2 have demonstrated the ability to 
completely halt the progression of cells at various stages of the cell cycle36. In addition, 
cdk-activating kinase (CAK), which is considered the master regulator of the cell cycle, 
is in turn regulated by CK237. This was determined using various point mutations in the 
sequence of cyclin H, a component in CAK, which lead to the observation that CK2 
phosphorylated cyclin H specifically at threonine 31538.  
With respects to the G1/S phase transition, the signal to initiate DNA replication 
involved hyper-phosphorylation of the retinoblastoma protein (pRB), which releases E2F 
transcription factor from an inhibitory state, such that it can initiate the transcription of 
several cell cycle genes39. Once the signal to begin DNA replication is transduced, CK2 
has been implicated in many ways not only to serve to ensure proper cell growth, but to 
rather supervise the progression throughout the cell cycle to secure a successful outcome. 
One way in which CK2 monitors the cell cycle is through its interactions with the tumor 
suppressor protein, p5335. In brief, p53 is induced by a signal indicating that some sort of 
cellular stress or DNA damage has been initiated, and in the case of UV damage to DNA, 
will be phosphorylated at serine 392 by CK240. This results in an increase of p53 binding 
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to DNA, as well as transcriptional activation of particular molecules such as p21 and 
p1641. In addition, it has been observed that CK2 and its interactions with p53 are 
mediated through the protein, Mdm242.  
In addition to CK2 and its role with p53 as a means of monitoring the signaling 
through the G1/S phase transition, CK2 has also been implicated in the G2/M transition 
of the cell cycle. In this circumstance, Cdk1 specifically phosphorylates CK2α in a cell 
cycle dependent manner, typically at residues T344/T360 and S362/S370, which are 
located within its unique C-terminus43,44. In addition, it has been determined that CK2β is 
also phosphorylated by Cdk1, although the significance of this event is not well 
understood45. In order to elucidate the significance of cell cycle dependent 
phosphorylation of CK2α, phosphospecific antibodies have been generated against the 
four phosphorylation acceptor sites on CK2α mentioned above. Immunoblot analysis 
detected the presence of phosphorylated CK2α in prophase and metaphase specifically. 
Furthermore, expression of non-phosphorylatable mutants of CK2α led to the induction 
of mitotic catastrophe45. It is also important to highlight that this serves as an additional 
example of functional specialization that may exist between the two catalytic subunits of 
CK2, since Cdk1 does not phosphorylate CK2α’ in a cell cycle dependent manner. In 
conclusion, the requirement for CK2 to phosphorylate, as well as be phosphorylated 
during various stages of the cell cycle only serve to support protein kinase CK2 as an 
important mitotic regulator. 
 
1.3.2 – CK2 and a role in cellular survival and apoptosis 
Another functional role of protein kinase CK2 building excitement in the field is 
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its implications in cellular survival and apoptosis. Protein kinase CK2 has been observed 
to play a fundamental role in cell survival, through maintaining cell viability and 
protecting cells from their apoptotic machinery. Interestingly, a reduction in viability was 
detected when expressing catalytically inactive forms of CK2, indicating the requirement 
of CK2 activity, and not just the presence of the kinase46. In addition, studies using 
genetically tractable yeast models to examine the necessity of protein kinase CK2 in 
maintaining viability demonstrated that down regulation of CK2 using temperature-
sensitive mutants resulted in a dramatic loss of viability47. Interestingly, a dramatic 
reduction in viability was only observed following the down regulation of both CK2α and 
CK2α’ catalytic subunits, suggesting that one may be able to functionally compensate for 
the other in the context of cellular viability. As previously noted, this is not however the 
case in mice since CK2α/ CK2β knockouts resulted in embryonic lethality, whereas 
knockouts of CK2α’ resulted in mice that were viable but developed defects in 
spermatogenesis29. This finding suggests that CK2α can compensate for the loss of 
CK2α’, whereas CK2α’ cannot compensate for the loss of CK2α. More significantly, this 
observation may serve to highlight the independent regulation that may exist between the 
two catalytic subunits of CK2 in the process of cellular viability.  
One highly studied mechanism by which CK2 functions in the protection of cells 
against apoptosis, is its phosphorylation of members of the apoptotic machinery. It has 
been observed that protein kinase CK2 can phosphorylate the pro-apoptotic protein, Bid, 
a member of the bcl-2 family, preventing downstream activation of mitochondrial 
apoptotic machinery48,49. Furthermore, CK2 has been implicated in the stimulation of 
inhibitor of apoptosis proteins (IAP’s), one in particular being survivin50. Collectively, 
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these outcomes prevent the activation of caspases, which are responsible for the 
execution of apoptosis. As mentioned earlier, CK2 has a plethora of cellular substrates, 
and in fact, caspases themselves fall into this category. Caspases are synthesized in a 
precursor form as zymogens, where in the presence of a cellular death signal, a cascade 
of caspase cleavage is induced, leading to activation of executioner caspases which 
implement cellular apoptosis51. A potential direct link between CK2 and caspases was 
revealed by the demonstration that phosphorylation of caspases by CK2 in proximity to 
their cleavage sites resulted in the overall protection of caspases from cleavage, thus 
halting the cascade responsible for the activation of executioner caspases51,52. Overall, it 
can be seen that CK2 unquestionably plays a significant role in the protection of cells 
from apoptosis, thus maintaining its role as a pro-survival player within cells. However, 
mounting evidence has suggested that it is these very cellular processes that are often 
manipulated in various human cancers, and CK2 might be at the center of such oncogenic 
activity.   
 
1.4 – Protein kinase CK2: Prospect for therapeutic targeting  
Elevated expression of protein kinase CK2 has been detected in many different 
cancers, including cancers of the kidney, breast, and prostate53–55. Further investigating 
the role of CK2 in tumorigenesis, Seldin and Leder (1995) provided evidence, which 
implicated CK2 in transformation by targeted overexpression of CK2 in transgenic mice, 
resulting in the development of leukemia56. Likewise, in hypoxia-associated tumors, 
histone deacetylases (HDAC’s) are activated in a CK2-dependant manner57. Overall, 
these findings ignited an exciting area of research directed at elucidating the role of CK2 
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in the development of tumorigenesis. Therefore, this section will highlight mechanisms 
identified by which CK2 may exhibit oncogenic activity and push the equilibrium 
towards cancer.   
 
1.4.1 – Regulation of tumor-suppressor proteins and oncogenes  
As mentioned earlier, CK2 plays central roles in cellular proliferation and survival 
in the context of normal cells, although it is typically these very processes that become 
hijacked and shift the physiological environment into one well suited for the development 
of cancer. In this respect, the role of CK2 in the normal regulation of the tumor 
suppressor protein, p53, preventing the replication of DNA at inopportune times, may 
often pose as a threat under cancerous conditions where CK2 levels are manipulated, and 
thereby establish improper control of the cell cycle. Another example of CK2 in the 
regulation of tumor suppressor proteins is the down regulation of the promyelocytic 
leukemia protein (PML), a phenomenon frequently observed in many human cancers58. 
Tumor suppressor protein, PML, is responsible for regulating pathways responsible for 
growth suppression, apoptosis, and senescence. Implicating CK2 in this regulation is its 
ability to phosphorylate PML, specifically at residue S51759. Furthermore, elevated CK2 
activity in a lung cancer mouse model is associated with an increase in the degradation of 
PML via the proteasome pathway60.  
In addition to the regulation of tumor suppressor proteins, CK2 has also been 
implicated in the stimulation of oncogenes, which encode for proteins responsible for the 
uncontrollable growth of cells61. In fact, CK2 has been speculated to reroute signals 
indicative of cell death into pathways promoting cell survival, providing a so-called 
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“pathological rewiring” of signal transduction pathways. One mechanism by which CK2 
can potentiate the elevated transcription of oncogenes is through the up regulation of the 
transcriptional-activator, NF-kB62. In general, NF-kB is found sequestered within the 
cytoplasm by an inhibitory protein, IkB, which becomes phosphorylated thus relieving 
NF-kB for activation of many genes important for cell survival and cell proliferation. 
With respects to regulation via CK2, it has been demonstrated that IkB is phosphorylated 
directly by CK2 at residue S529, providing a means of NF-kB inhibitory release that is 
alternative to the canonical IKK kinases pathway63. In addition, evidence supports that 
CK2 directly phosphorylates p65, a family member of NF-kB resulting in an increase in 
DNA-binding potential64. 
Overall, from these observations it becomes evident that CK2 may promote 
tumorigenesis through the manipulation of those proteins that serve as gatekeepers to 
prevent deleterious effects of cellular stress, as well as proteins that tend to promote the 
uncontrollable growth of cells. In addition, it has been considered that CK2 promotes a 
synergistic effect via the ability to promote increased expression of oncogenes in those 
very cells that also tend to lack tumor suppressor proteins, serving as an additive force to 
drive the equilibrium in favour of a tumorigenic environment65. 
 
1.4.2 – CK2 and apoptosis in cancer 
Not only is cancer a consequence of uncontrollable cellular proliferation, but it 
also becomes an issue of cells not being able to make timely cellular decisions of life and 
death, ultimately choosing to promote cell survival at times when apoptosis would be 
beneficial and visa versa. As mentioned earlier, CK2 possesses the ability to regulate 
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members of the apoptotic machinery, namely those of the caspase family, resulting in the 
protection of downstream cleavage due to the phosphorylation of overlapping consensus 
sequences51,52. Accordingly, it can be seen that prevention of apoptosis under situations 
such as uncontrolled growth or intracellular damage, could be detrimental to the normal 
life cycle of that cell, and may help to shift the balance in support of tumorigenesis. 
Recently, an additional mechanism by which CK2 plays a protective role towards 
cellular apoptosis is through a multiple-drug resistance phenotype. Through previous 
work performed by Ahmed and colleagues (1993), it was demonstrated that CK2 was 
dynamically regulated in terms of nuclear localization, and that this regulation was 
dependent on the strength of growth stimuli66,67. In particular, removal of androgenic 
growth signals from prostate epithelial cells in rats resulted in a significant reduction in 
levels of CK2 associated with the nuclear matrix, and could be replenished by 
regenerating androgenic stimuli into the cells68. In addition, it was recently demonstrated 
that reduction of CK2 from the nuclear matrix was associated with intense induction of 
apoptosis in an in vivo prostate tumor model69. This observation led to the hypothesis that 
CK2 may be imparting a protective role towards apoptosis when localized to the nuclear 
matrix. To test this hypothesis, chemical-inducing apoptotic compounds, etoposide and 
diethylstilbestrol (DES), were utilized. It was demonstrated that after treatment with both 
etoposide and DES, there was a significant increase in the localization of CK2 to the 
nuclear matrix, which ultimately led to a protective phenotype towards apoptosis70. This 
result is opposite of what is observed during receptor-mediated apoptosis, where a 
considerable reduction in the levels of CK2 associated with the nuclear matrix is 
observed70. Collectively, this identified a potential protective role for CK2 in drug-
	  	  
15	  
induced apoptosis.  
Despite the fact that the overexpression of CK2 in many cancers has been 
associated with a protective role towards apoptosis, recent experiments have shed light on 
the ability to sensitize cancer cells to apoptosis following a reduction in the levels of 
CK271. To date, the down regulation of CK2 has commonly been achieved using RNA 
silencing (siRNA) techniques to selectively knock down the different subunits of CK2. 
Using this strategy, it was observed that there was a dramatic loss of cell viability (80%) 
in the ALVA-41 cancer cell line compared to the normal control (30%) following siRNA 
targeting of CK271. This serves to reiterate the anti-apoptotic role for CK2 within cells. In 
addition to siRNA approaches, catalytically inactive forms of CK2 have also been 
engineered to determine the cellular consequences of down regulating CK2 activity in 
cancer cells. Similar to the effects observed from siRNA approaches, there was a 
significant reduction in cellular viability (75%) following transfection with catalytically 
inactive CK2, compared to the control, which only was slightly effected71. However, this 
strategy can often be challenging since the down regulation of CK2 via knockdown is 
often incomplete.  
Accordingly, small molecule-inhibitors are rising as a promising tool for the 
inhibition of CK2, as this is predicted to inhibit all endogenous levels of CK272. Overall, 
investigation into the inhibition of CK2 using chemical inhibitors will serve to elucidate 
the molecular mechanisms by which CK2 guides decisions of life and death within cells, 
as well as to provide insight into the future of therapeutic intervention towards those 
cancers in which elevated expression of CK2 is observed.  
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1.4.3 – Chemical inhibition of protein kinase CK2 
Based on its roles in cancer and the prospect for the inhibition of CK2 for therapeutic 
intervention, interests have been sparked in the development of chemical inhibitors of 
CK2. To this point, many inhibitors have been generated and their potency, as well as 
their selectivity has been tested in vitro73–75 (Figure 2). Initially, inhibitors targeting CK2 
were derived from an ancestral compound (5,6-dichloro-1-(b-D-ribofuranosyl)-
benzimidazole) (DRB), originally described in 198676 that subsequently led to the 
development of more widely employed CK2 inhibitors tetrabromobenzotriazole (TBB) 
and tetrabromobenzimidazole (TBBz)77. Testing these compounds against a broad panel 
of different kinases as an indication of their selectivity, demonstrated that TBB was quite 
selective towards CK278. The derivative, TBBz, although not as selective towards CK2 as 
TBB, indicated its potential at better discriminating between the various isoforms of 
CK273. Kinetic parameters have been determined for these compounds in vitro, indicating 
a range of Ki values of 80-210 nM for TBB, and a range of Ki values of 70-510 nM for 
TBBz73. Although these compounds have for some time been recognized as common 
inhibitors for targeting CK2, many attempts to improve the efficacy of CK2 inhibitors 
have been implemented, thereby utilizing TBB has a forerunner for the development of 
more potent and selective inhibitors. An example is the compound, DMAT, resulting 
from the derivitization of the imidazole ring of TBBz that proved to be more potent than 
TBB when exposed to cell cultures79.  
More recently, a newly designed and first orally available ATP-competitive 
inhibitor of CK2, CX-4945, was developed by Cylene Pharmaceuticals74. The  
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Figure 2. Structure of ATP, GTP, and current inhibitors of protein kinase CK2 
Chemical structures of ATP, GTP, and characterized inhibitors of protein kinase CK2. 
Previously reported IC50 values have also been included.   
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derivatization of CX-4945 was achieved through the optimization of a PARP inhibitory 
compound, selected from a library due to its structural similarity to [[5-­‐oxo-­‐5,6-­‐dihydro-­‐indolo(1,2-­‐a)quinazolin-­‐7-­‐yl]acetic	  acid] (IQA), another inhibitor of protein kinase 
CK2. More specifically, a series of substitutions to incorporate amino alkyl chains 
bearing aniline moieties and replace the existing thiophene ring with a pyridine, led to the 
production of the more potent CX-4945 compound74. Biological characterization of CX-
4945 using in vitro enzymatic assays showed that when compared against a panel of 235 
other protein kinases, CX-4945 was selective for CK274. In addition, CX-4945 has been 
shown to be considerably more potent than other current existing inhibitors of CK2, with 
a reported Ki of 0.38 nM74,80. Elucidating the biological consequence of CK2 inhibition 
by CX-4945, it was determined that the pro-survival PI3’K/AKT pathway was 
attenuated81. This conclusion arose from the inability to detect the CK2-specific 
phosphorylation of Akt at residue S129, as well as the canonical regulatory residues, 
S473 and T30881. In addition, dephosphorylation of downstream targets of Akt such as 
p21 was also observed81. Subsequent studies have since been performed to evaluate the 
therapeutic potential of CX-4945 as an anti-cancer agent. Providing evidence in support 
of an anti-proliferative role for CX-4945 in cancer is its ability to induce cell cycle arrest 
and initiate apoptosis in PC3 prostate carcinoma cells74. Furthermore, CX-4945 has 
demonstrated the capacity to potentiate anti-tumor activity in a mouse xenograft model, 
inhibiting tumor growth by nearly 86%74. Although CX-4945 has primarily been 
described as an inhibitor of pro-survival pathways, evidence has also indicated its ability 
to prevent tube formation and transcription of the hypoxia-induced factor 1α (HIF-1α) in 
models of angiogenesis, as well as suppress the production of the inflammatory 
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interleukin-6 in human breast cancer cells81. Overall, CX-4945 is considered to be a 
promising therapeutic modulator of protein kinase CK2, and due to its successes in the 
treatment of various cancers indicating its potential as a clinical inhibitor, CX-4945 was 
subjected to clinical trails with recent advancement into phase II trails82. 
Although the current panel of CK2 inhibitors being designed, synthesized, and 
characterized is continuing to grow, and evidence behind their potency and selectivity 
towards CK2 has been well documented, the majority of these studies have only been 
performed in vitro83–85. As a result, there tends to be a lack of evaluation for these 
inhibitors regarding their modulation of the biological and pathological roles of CK2 
within cells. Whether or not the observed effects are a direct or indirect consequence of 
targeting CK2 also often remains to be explored, limiting our understanding of the 
potential off-targets that could influence the behavior of a given inhibitor. Therefore, the 
development of a strategy to effectively and rapidly evaluate current and novel inhibitors 
of protein kinase CK2 could be instrumental to further expand our understanding of the 
consequences of CK2 inhibition in cells, as well as unveiling valuable information that 
may help advance these inhibitors for clinical applications.  
 
1.5 – The use of inhibitor-refractory mutants for the study of protein kinases 
Although the development of mutants that are rendered insensitive to inhibition 
by specific inhibitors may sound counterproductive and perhaps troublesome, considering 
the prevalence of drug resistance in the clinical setting, their use as a tactical tool in order 
to elucidate information regarding a protein of interest can be insightful. For example, in 
a recent study performed by Fujiwara and colleagues (2015), drug-resistant mutants in 
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combination with a specific inhibitor were utilized in order to assess isoform specificity 
of the Ca2+/calmodulin- dependent protein kinase kinase (CaMKK)- mediated signaling 
pathways86. They were particularly interested in distinguishing whether it is CaMKKα, 
CaMKKβ, or both that are responsible for the phosphorylation and activation of the 
downstream proteins, AMPK and CAMKIV. Their findings illustrated that the 
suppression of the ionomycin-induced phosphorylation (Thr172) and activation of 
AMPK due to treatment of A549 cells with a CaMKK inhibitor (STO-609), was relieved 
following the expression of an inhibitor-insensitive mutant of CaMKKβ, but not 
CaMKKα. In contrast, they observed that the ionomycin-induced phosphorylation 
(Thr196) and activation of CAMKIV was no longer suppressed following the expression 
of inhibitor-insensitive mutants of both CaMKKα and CaMKKβ.Together, these data 
suggest that the utilization of inhibitor-resistant mutants of protein kinases in 
combination with specific inhibitors can serve to distinguish isoform-specific 
phosphorylation events in cells.  
 Studies have also demonstrated that the development of kinases that are rendered 
insensitive to inhibition can provide a means for evaluating the effects of current and 
novel inhibitors in cells. An example of this utility is displayed in the work performed by 
Eyers et al (1999) confirming the in vivo effects of an inhibitor, SB 203580, for the 
stress-activated protein kinase 2a/p38 (SAPK2A/P38)87. It was demonstrated that the 
phosphorylation and activation of four well established downstream targets of the stress-
activated protein kinase 2a/p38 were suppressed in the presence of the SB 203580 
compound. To determine if these effects were a result of the specific inhibition of the 
SAPK2A/P38 kinase, they generated a cell line that readily expressed a drug-resistant 
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mutant. Following the expression of the drug-resistant SAPK2A/P38 kinase, they 
observed that the downstream phosphorylation and activation events were no longer 
suppressed. Importantly, if the observed effects of the SB 203580 compound were due to 
targeting a non-specific kinase, then the expression of a drug-resistant mutant of 
SAPK2A/P38 should have no effect on the phosphorylation status of the four 
downstream targets. Therefore, the researchers were confident that the effects of the SB 
203580 compound were exerted through specifically targeting the SAPK2A/P38 protein 
kinase.  
Overall, we can begin to envisage how the creation of stable cell lines, that readily 
express inhibitor-insensitive mutants of the various isoforms of CK2, may pave the way 
for the effective and rapid separation of their catalytic activity in cells. This would be a 
significant achievement, as it would allow us to more precisely investigate the functional 
roles that CK2 may orchestrate within cells, and in particular, help to distinguish 
functions that may be isoform-specific from those that are compensatory. Additionally, 
creation of a system that allows the separation of catalytic activity exhibited by the 
various isoforms of CK2 will provide a platform that will enable a thorough evaluation of 
current and novel inhibitors, which has previously been unattainable.  
To achieve the goal of engineering inhibitor-refractory mutants of CK2, our 
expectation is that we can use the structural basis for its inhibition to rationally identify 
those residues that are responsible for the tight binding of specific inhibitors to the active 
site of CK231,35,88,89. We can also utilize kinase alignments to identify the residues that 
exist within other kinases at the positions of interest where key inhibitory determinants 
identified in CK2 reside. To generate inhibitor-refractory mutants of CK2, we will 
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substitute the key structural determinants for the binding of inhibitors to CK2, in order to 
make CK2 resemble kinases in which the inhibitors are not selective. Ultimately, we 
believe that cell lines expressing mutants of CK2 that are noticeably less sensitive to 
inhibition will serve as a tactical tool for the future study of protein kinase CK2 and 
evaluation of its inhibitors. Towards these objectives, this thesis describes the 
development and characterization of mutants of the CK2α isoform that display a reduced 
sensitivity to inhibition by the well-known CK2 inhibitor, CX-4945. In particular, the 
work described in this thesis is focused on investigations of singe, double, and triple 
mutants of CK2α bearing combinations of the V66A, H115L, H160D, and I174A amino-
acid substitutions.  
 
1.6 – Rationale, hypothesis, and objectives 
1.6.1 - Rationale 
Within the last decade, several investigations into the structural basis behind the 
binding of inhibitors to the active site of protein kinase CK2 have been performed25,31,89–
91. Many important observations have since been documented, most noteworthy being the 
repeated identification of two hydrophobic residues, valine 66 (V66) and isoleucine 174 
(I174)31,73,78,92,93. Interestingly, these residues appear to be unique to CK2 since 
comparative analysis of other protein kinases revealed that the majority of protein kinases 
contained the much smaller amino acid, alanine89,94. This suggested that CK2 might 
contain a unique structural feature within its catalytic pocket that could be exploited for 
the development of CK2 selective inhibitors. Examination of the high-resolution structure 
of CK2α with CX-4945 (Figure 3: PDB code 3PE1, V66 in orange and I174 in pink), it is 
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clear that the hydrophobic residues, V66 and I174, are positioned above and below the 
inhibitor respectively, presumably functioning as a clamp in order to provide further 
stabilization for the inhibitor within the active site of CK231. It was therefore predicted 
that by substituting these residues to alanine, in order to make CK2 resemble the majority 
of the remaining protein kinases, the selectivity of CK2 inhibitors for the binding of its 
active site could be lost, generating a mutant that is less sensitive to inhibition. In fact, 
mutational studies have demonstrated that substitution of these residues to smaller amino 
acids such as alanine, can influence the ability of CK2 inhibitors to inhibit CK2, as 
reflected by the dramatic change in Ki31,73. These findings are promising because they 
demonstrate that the generation of mutants that are catalytically active but yet display a 
reduced sensitivity to inhibition is feasible. To build on these observations, a central 
emphasis of the work described in this thesis has been directed towards the creation of 
tetracycline-inducible cell lines expressing a mutant of CK2α bearing the V66A and 
I174A mutations. Since there have been indications that additional residues may also be 
involved in the binding of CK2 inhibitors, I have also been evaluating the prospects that 
the generation of a new mutant with an increased ability to impair the inhibition of CK2 
is attainable.  
 Although it has been considered that the hydrophobic interactions primarily 
established by the V66 and I174A residues are the main energetic contributors towards 
the binding of CK2 inhibitors, evidence suggests that electrostatic interactions and the 
formation of extensive hydrogen bond networks can also play a significant role31,95. In 
fact, a recent structural study investigating the selectivity of the CK2 inhibitor, CX-4945,  
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Figure 3. Illustration of important residues implicated in the binding of CX-4945 
The co-ordinates (PDB identification number 3PE1) from the high-resolution crystal 
structure of the CK2 tetramer31 were combined with PyMol to generate a ribbon diagram 
representing the CK2α holoenzyme. I have zoomed in on one CK2α catalytic subunit 
bound to the CK2 inhibitor, CX-4945, in order to highlight the residues important for its 
stabilization within the active site of CK2. Valine 66 (V66) is indicated in orange, 
histidine 115 (H115) is indicated in purple, histidine 160 (H160) is highlighted in red, 
and isoleucine 174 (I174) is highlighted in pink. 
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for the active site of protein kinase CK2 has identified a basic residue, H160, located 
directly below the phenyl group containing a chlorine moiety31,90. It is reasonable to 
believe that a histidine residue bearing a positive charge could be functioning to stabilize 
the inhibitor (CX-4945) by establishing strong electrostatic interactions with the 
chlorophenyl moiety. However, it was observed that when in the presence of the inhibitor 
(CX-4945), H160 was locked into an “upward” conformation in order to make bridging 
interactions to the chlorophenyl group through a conserved water molecule (W2) located 
within the protein matrix31,90. In addition, although there is no evidence to date 
suggesting a role in the binding of CX-4945 to the active site of CK2α, the residue H115 
has been implicated in the binding of a structurally related inhibitor, CX-527931. As a 
result of their recent implications for the binding of inhibitors into the active site of CK2, 
I subsequently decided to resort back to the comparative analysis of protein kinases 
constructed by Hanks and Hunter94 (1999) to determine if these residues are also 
structurally unique to the protein kinase CK2 (as were residues V66 and I174)(Table 1: 
adapted from Hanks & Hunter, 1999 – CK2α is bolded and the unique residue is 
highlighted in red). I determined that these residues (H115 and H160) were in fact 
exclusive to the protein kinase CK2, suggesting another unique structural feature that 
may enable its selective inhibition. Accordingly, I expect that these residues would be 
prime candidates for substitution in order to further impair the ability of inhibitors to 
inhibit CK2, and therefore I now wanted to determine what residues I should consider for 
their replacement.  
Similar to the strategy employed in order to determine the appropriate residue for the 
substitution of the previously established V66 and I174, I decided to identify what 
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residues other kinases contained at the positions of interest (H115 and H160). The 
rationale behind this strategy is that if the residues, H115 and H160, are exclusive to 
protein kinase CK2 and are responsible for the selective nature of its inhibitors, then by 
replacing these residues in order to make a mutant of CK2 that resembles the majority of 
other protein kinases, I would expect to render CK2 less sensitive to the inhibitor. It was 
determined that the majority of protein kinases contained leucine/tyrosine (L/Y) and 
aspartic acid/glutamic acid (D/E) residues at positions 115 and 160, respectively (table 1). 
The histidine residue at position 115 (H115) was substituted to a leucine residue 
(H115L), since the α’ isoform of CK2 contains a tyrosine residue at that position (Y115), 
which would presumably maintain the selectivity of CX-4945 for CK2, since both 
catalytic subunits of CK2 are inhibited by CX-4945. The histidine residue at position 160 
(H160) was substituted for an aspartic acid (H160D). The rationale for this decision 
stemmed from the previous exploration into the susceptibility of different protein kinases 
to inhibition by staurosporine, which highlighted the H160D amino-acid substitution in 
CK2α96. In that report, it was demonstrated that CK2α bearing a H160D mutation was 
less sensitive to a staurosporine derivative (CGP44171A), which is more effective than 
staurosporine for the inhibition of CK2. 
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Table 1: Protein kinase alignment highlighting non-conserved residues in CK2α. 
Adapted from Hanks and Hunter97 (1995) 
Kinase  2° Structure (60-80) 
PKA 
PKG 
PKC 
DMPK 
CaMK2α 
Polo 
Cdc5 
Cdk2 
Erk2 
GSK3α 
CK2α 
clk 
Ire1 
Cdc7 
Cot 
YpkA 
MEK1 
Ste7 
Ste11 
Nek1 
 TGNHYAMKILDKQKVVKLK 
 ESKTFAMKILKKRHIVDTR 
 TEELYAIKILKKDVVIQDD 
 TGQVYAMKIMNKWDMLKRG 
 AGQEYAAKIINTKKLSAR 
 TDTVFAGKIVSKKLMIKHN 
 SGEIFAAKTVAKASIKSEK 
 TGEVVALKKIRLDTETEG 
 NKVRVAIKKISPFEHQT 
 TRELVAIKKVLQ 
 NNEKVVVKILKPV 
 GGRHVAVKIVKNVDR 
 QGRPVAVKRMLID 
 GSNYVALKKIYVTS 
 TKKRMACKLIPVD 
 DKQRLVAKIERSIAE 
 SGLVMARKLIHLEIKPA 
 DSKIVAKKTIPVEQNNST 
 TGELMAVKQVEIKNNIG 
 DGRHYVIKEINISRMSDK 
 
Kinase 
 
2° Structure (107-118) 
PKA 
PKG 
PKC 
DMPK 
CaMK2α 
Polo 
Cdc5 
Cdk2 
Erk2 
GSK3α 
CK2α 
Clk 
Ire1 
Cdc7 
Cot 
YpkA 
MEK1 
Ste7 
Ste11 
Nek1 
  SNLYMVMEYVPG 
  KYLYMLMEACLG 
  DRLYFVMEYVNG 
  NYLYLVNEYYVG 
  GHHYLIFDLVTG 
  QNIYIVLELCKK 
  SNVYILLEICPN 
  NKLYLVFEFLHQ 
  KDVYIVQDLMET 
  LYLNLVLEYVPE 
  RTPALVFEHVNN 
  GHICIVFELLGL 
  RFLYIALELCNL 
  DQVIAVLPYYPH 
  ETVHLFMEAGEG 
  LMDEVDGWRCSD 
  GEISICMEHWDG 
  NEIIILMEYSDC 
  GNLNIFLEYVPG 
  GSLYIVMDYCEG 
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Table 1: Protein kinase alignment highlighting non-conserved residues in CK2α 
Adapted from Hanks and Hunter97(1995) 
Kinase 2° Structure (150-170) 
PKA 
PKG 
PKC 
DMPK 
CaMK2α 
Polo 
Cdc5 
Cdk2 
Erk2 
GSK3α 
CK2α 
clk 
Ire1 
Cdc7 
Cot 
YpkA 
MEK1 
Ste7Ste11Nek1 
  DLIYRDLKPENLLIDQQ 
  GIIYRDLKPENLILDHR 
  GIIYRDLKLDNVMLDSE 
   GYVHDIKPDNILLDRC 
  GVVHRDLKPENLLLASKLKG 
  RIIHRDLKLGNLFLNDL 
  RVIHRDLKLGNIFFDSN 
  RVLHRDLKPQNLLINTE 
  NVLHRDLKPSNSSLNTT 
  GVCHRDIKPQNLLVDPDT 
  GIMHRDVKPHNVMIDHEH 
  KLTHTDLKPENILFVQSD 
  KIIHRDLKPQNILVSTSS 
  GIIHRDIKPTNFLFNLEL 
  KVIHHDIKPSNIVFMS 
  GVVHNDIKPGNVVFDRAS 
  KIMHRDVKPSNILVNSR 
  KIIHRDIKPSNVLIVSK  
NIIHRDIKGANILIDIK  
KILHRDIKSQNIFLTKD 
 
Kinase 
 
2° Structure (169-186) 
PKA 
PKG 
PKC 
DMPK 
CaMK2α 
Polo 
Cdc5 
Cdk2 
Erk2 
GSK3α 
CK2α 
clk 
Ire1 
Cdc7 
Cot 
YpkA 
MEK1 
Ste7 
Ste11 
Nek1 
   GYIQVTDFGFAKRVKG 
   GYAKLVDFGFAKKIGFGK 
   GHIKIADFGMCKEHMMDGV 
   GHIRLADFGSCLKLRADGTV 
   AAVKLADFGLAIEVEGEQQ 
   LHVKIGDFGLATRIEYRGE 
   YNLKIGDFGLAAVLANESE 
   GAIKLADFGLARAFGVPVR 
   CDLKICDFGLARVADPDHDHTG 
   AVLKLCDFGSAKQLVRGE 
   RKLRLIDWGLAEFYHPGQ 
   PDIKVVDFGSATYDDE 
   LRILISDFGLCKKLDSGQS 
   GRGVLVDFGLAEAQMDYK 
   TKAVLADFGLSVQNTEDVY 
   GEPVVIDLGLHSRS 
   GEIKLCDFGVSGQLIDS 
   GQIKLADFGVSKKLINS 
   GCVKITDFGISKKLSPLN 
   GTVQLADFGIARVLNSTVE 
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1.6.2 – Hypothesis  
Therefore, in light of the evidence indicating that residuesV66, H115, H160, and I174 
are exclusive to CK2α, as well as the evidence supporting that the amino acid 
substitutions, V66A, H160D, and I174A can influence the efficacy of inhibitors towards 
CK2, I hypothesize that these mutations will affect the ability of CX-4945 to inhibit 
CK2α. If correct, this will be reflected by changes in the Ki, as well as in the recovery of 
CK2 activity following treatment with CX-4945. 
 
1.6.3 – Objectives  
In order to accomplish the goal of the study, I have two central objectives. First, I will 
perform an in vitro evaluation of recombinant CK2α mutants to identify the mutant that 
demonstrates the greatest ability to affect the inhibition of CK2 by CX-4945. Second, I 
will generate a tetracycline-inducible stable cell line such that I can achieve regulated 
expression of this mutant in a cellular system. The experimental workflow is outlined in 
Figure 4. I will begin by performing site-directed mutagenesis in order to incorporate the 
H115L and H160D mutations into either wild type CK2α, or a mutant of CK2α already 
containing the previously established V66A and I174A amino-acid substitutions. 
Subsequently, I will employ in vitro kinase assays to assess the effects of these amino 
acid substitutions on the inhibition of CK2 by CX-4945. Once the mutation that 
demonstrates the greatest ability to affect the ability of CX-4945 to inhibit CK2 has been 
identified, I will utilize Flp-In™ T-REx™ technology98 to incorporate the mutant of 
interest into a U2OS host cell line. Following the successful incorporation of the mutant 
of interest into the U2OS host cell line, a detailed characterization to examine the 
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conditions required to achieve optimal expression will be performed. Lastly, if I can 
identify a cell line whose expression of the mutant of interest is rapid, abundant, and 
tightly controlled by the presence or absence of tetracycline, then I will use this cell line 
to examine the effect of this mutant on the ability to affect the inhibition of CK2 by CX-
4945 in cells. Overall, I expect that these studies will provide new opportunities to utilize 
a mutant of CK2α that is noticeably less sensitive to inhibition as a tool that would surely 
benefit our ability to study the protein kinase CK2 in cells and to discriminate between 
the CK2-dependent and CK2-independent effects of the inhibitor. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	  	  
33	  
 
 
 
 
 
 
 
 
 
Figure 4. Experimental workflow 
A schematic illustration highlighting the experimental blueprint for this thesis. The 
experiment design consists of two central objectives. 1) In vitro evaluation of 
recombinant CK2α mutants on their ability to effect CK2 inhibition by CX-4945. 2) 
Generate a tetracycline-inducible stable cell line to test the effects of expressing a CK2α 
inhibitor-refractory mutant on the cellular response of CX-4945 
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2. Materials and Methods  
2.1 – Plasmid constructs  
2.1.1 GST-tagged mutants of CK2α 
 Plasmids encoding glutathione-S-transferase (GST)-tagged (a 220 amino acid 
fragment, originally described by Broek D, et al99) mutants of the CK2α catalytic subunit 
were generated for purification and use in in vitro kinase assays. Inhibitor-refractory 
mutants of CK2α containing H160D or H115L amino acid substitutions were generated 
using a site-directed mutagenesis approach via the polymerase chain reaction (PCR), the 
phusion DNA polymerase (Pfu, Thermo Scientific), and either a GST-CK2α or double 
mutant GST-CK2α (V66A/I174A) template to generate single and triple mutants. Primers 
utilized to introduce the various mutations into GST-CK2α are listed in Table 2. 
Following completion of PCR, all products were treated with restriction enzyme (Dpn1, 
NEB) for 30 minutes at 37°C. The amplified fragments for each mutant were verified by 
sequencing using the pGEX 5’ primer (GGGCTGGCAAGCCACGTTTGGTG, 3' end of 
GST tag). Plasmids containing the mutations of interest were then subjected to 
purification (see section 2.2 - protein production and purification).  
 
2.1.2 HA-tagged CK2α mutants for Flp-In cell line development 
To develop stable cell lines with the tetracycline-inducible expression of CK2α-
HA and CK2α (V66A/H160D/I174A)-HA, plasmid constructs were constructed for 
transfection into Flp-In U2OS cells. Both constructs contained the CK2α catalytic subunit 
with a C-terminal HA tag to help distinguish the expression of exogenous from 
endogenous protein. The HA-tag consists of a triple repeat of the influenza haemaglutinin 
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Table 2: Primers for generation of CK2α mutants 
Mutation Strand Primers (5’ to 3’) 
H115L 
 
 
H160D 
 
 
Sense 
Anti-sense 
 
Sense 
Anti-sense 
 CCGCCTTGGTTTTTGAACTCGTAAACAACACAGACTT 
AAGTCTGTGTTGTTTACGAGTTCAAAAACCAAGGCGG 
 
CACAGAGATGTCAAGCCCGATAATGTCATGATTGATC 
GATCAATCATGACATTATCGGGCTTGACATCTCGTG 
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epitope YPYDVPDY, as previously described100. In order to develop stable cell lines 
expressing CK2α-HA or CK2α (V66A/H160D/I174A)-HA, it required the transfer of the 
coding sequence from a pBI-vector backbone containing CK2α-HA or CK2α 
(V66A/I174A)-HA into the pcDNA5 Flp-In vector (Invitrogen). This was achieved by 
treating the pBI constructs with restriction enzymes, HindIII and ApaI for 2 hours at 
37°C and 25°C respectively. Constructs were verified via sequencing (Robarts 
Sequencing Facility). The pcDNA5 construct containing CK2α-HA was used for 
transfection into Flp-In U2OS cells. The pcDNA5 construct containing the CK2α 
(V66A/I174A)-HA double mutant served as a template for the PCR-based site-directed 
mutagenesis to incorporate the H160D amino-acid substitution into the pcDNA5 Flp-In 
expression vector. Successful incorporation of the H160D mutation was verified via 
sequencing (Robarts Sequencing Facility), and the pcDNA5 construct containing the 
CK2α (V66A/H160D/I174A)-HA triple mutant was used for transfection into Flp-In 
U2OS cells. (See table 3 for primers). 
 
2.2 – Protein production and purification  
GST-CK2α, GST- CK2α (H115L), GST- CK2α (H160D), GST- CK2α 
(V66A/I174A), GST- CK2α (V66A/H115L/I174A), and GST- CK2α 
(V66A/H160D/I174A) proteins were produced in BL21 E. coli transformed with the 
respective plasmid DNA and grown in 2xYT media (16g tryptone, 10g yeast extract, 5g 
NaCl, 1L ddH2O, pH 7.0) at 37°C until an optical density of 0.5 at 600 nm had been 
reached.  Protein expression was induced by the addition of 1 mM IPTG for 16 hours at 
16°C followed by centrifugation (5000 X g) for 15 minutes at 4°C.  Pellets were 
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resuspended in 30 mL of ice-cold phosphate-buffer saline (PBS) with protease inhibitors 
(1 mM PMSF, 7 µg/mL PepA, 20 µg/mL leupeptin, and 2.9 µg/mL aprotinin) and a 
homogenizer was used to lyse the cells. Triton-X100 (10%) was added to a final 
concentration of 1% to the total lysate volume and the suspension was tumbled for 15 
minutes at 4°C. The mixture was subsequently centrifuged at 13,000 X g for 15 minutes 
at 4°C to clear the supernatant. The supernatant was transferred into a 50 mL falcon tube 
and 2 mL of freshly prepared glutathione-agarose beads (Sigma) were added, mixed, and 
tumbled for 1 hour at 4°C. The mixture was centrifuged at 2000 x g for 2 minutes at 4°C 
in order to pellet the beads containing bound proteins. The beads were resuspended in 8 
mL of cold PBS and transferred into a 10 mL gravity column. Non-specifically bound 
proteins were washed with 10 column volumes of cold PBS with protease inhibitors. The 
remaining bound proteins were eluted by washing the column with elution buffer 
containing increasing concentrations of glutathione (2 x 1 mL fractions of 10 mM 
glutathione elution buffer (10 mM reduced glutathione, 50 mM Tris-HCl pH 8.0, 1 mM 
DTT) followed by 5 x l mL fractions of 30 mM glutathione elution buffer (30 mM 
reduced glutathione, 50 mM Tris-HCl pH 8.0, 1 mM DTT)). A 20 µL sample of all eluted 
fractions from each purified protein was analyzed on a 12% SDS-PAGE gel that was 
stained with Coomassie Blue and destained with water in order to visualize proteins. 
Fractions containing GST- CK2α or the GST- CK2α mutants protein were combined and 
dialyzed into a storage buffer containing 50 mM Tris-HCl pH 7.5, 200 mM NaCl, 1 mM 
EDTA, 1 mM DTT, and 50% glycerol for future use in in vitro kinase assays. A 
comparative analysis of each purified protein can be seen in Table 3. 
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2.3 – Cesium-chloride plasmid purification 
In order to achieve high efficiency when transfecting plasmid DNA into 
mammalian cells, cesium-chloride (CsCl) purification was performed to isolate super-
coiled DNA species. Briefly, pcDNA5 Flp-In (Invitrogen) constructs expressing CK2α-
WT, CK2α-V66A/I174A, or CK2α-V66A/H160D/I174A were transformed into DH5α 
cells and grown overnight (16 hours) in LB media containing 1 mM ampicillin at 37°. 
The bacterial cultures were subsequently centrifuged at 13,000 x g to collect a bacterial 
pellet and the CsCl purification was performed as previously described101. After 
completion of the CsCl purification, 1 µL of each sample was applied to a nano-drop in 
order to determine DNA concentration (µg/µL). Finally, 500 ng of each sample was 
processed on an agarose gel to visualize the quality of the DNA. 
 
2.4 – In vitro kinase assays 
2.4.1 – Assessing activity of GST-CK2α mutants 
To assess the activity of GST-CK2α and the GST-CK2α mutants, I performed in 
vitro kinase assays. Bacterially expressed GST-CK2α and GST-CK2α mutants were 
purified as previously described and were used as the source of kinase for each reaction. 
Activity assays were prepared by the addition of 4 µL of 5X kinase reaction buffer (50 
mM Tris buffer, pH 7.5,10 mM MgCl2, [γ-32P] ATP (1 µL per 100 µL of reaction buffer), 
with 2 µL of RRRDDDSDDD peptide (5 mg/ml, CK2 substrate), and the appropriate 
amount of ddH2O in order to bring the reaction volume to 16 µL. Each reaction was 
performed with increasing concentrations of cold ATP (0 - 400 uM). Finally, 200 ng of 
GST-CK2α or one of the GST- CK2α mutants (4 µL of kinase) were added at 15-second 
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intervals in order to start each reaction. Samples were incubated in a water bath at 37°C 
for 10 minutes and 10 µL of each reaction was spotted onto P81 phosphocellulose paper. 
To halt the reaction and remove any remaining 32P-γATP that may not have been 
incorporated into substrate, the spotted P81 paper was washed 4 times in 10 mL of 1% 
phosphoric acid solution, once in 10 mL of ethanol, and set aside to dry under a heat 
lamp for 5-10 minutes. Dried P81 paper was exposed to a phosphorimaging screen 
(Amersham Biosciences) for one hour and analyzed using a Storm phosphorimager 
(Storm 860 Molecular Imager) to detect the level of 32P-labelled substrate bound to the 
P81 paper. The amount of 32P incorporated onto the RRRDDDSDDD peptide is directly 
proportional to the catalytic activity of CK2α.  
 
2.4.2 – Effect of GST-CK2α mutants on inhibition by CX-4945 
  To determine the effect of GST- CK2α mutants on the Ki of CX-4945, activity 
assays were performed. Reaction mixtures (final volume 20 µL) were prepared by the 
addition of 4 µL of 5X kinase reaction buffer (50 mM Tris buffer, pH 7.5, 100 mM NaCl, 
12 mM MgCl2, plus [γ-32P] ATP (1 µL per 100 µL of reaction buffer)), 2 µL of 0.1 mM 
RRRDDDSDDD peptide (a CK2 substrate), and either no inhibitor (DMSO), 1 nM, or 10 
nM CX-4945. Each reaction was also prepared with various concentrations of ATP (0-
100 µM). The appropriate amount of ddH2O was added to bring the reaction volume up 
to 16 µL. To start the kinase reaction, 180-260 ng (table 3: amount of kinase/20 µL 
reaction in order to normalize activity) of the appropriate form of CK2 (4 µL of either 
GST- CK2α or one of the GST- CK2α mutants) was added to the reaction mixture at 15- 
second intervals in order to test each concentration of inhibitor against each 
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Table 3: Comparison of purified GST-CK2α and GST-CK2α mutants 
Kinase	  
(GST-­‐CK2α)	  
Concentration	  	  
(mg/mL)	   Specific	  activity	  (pMol/min/μg)	   Kinase	  (ng)/20μL	  
reaction	  
(Normalization)	  
	  WT	  	  H115L	  	  H160D	  	  V66A/I174A	  	  V66A/H115L/I174A	  	  V66A/H160D/I174A	  
	  6.06	  	  7.25	  	  1.42	  	  2.20	  	   2.45	  	   1.39	  
	   474	  	  507	  	  524	  	  352	  	   397	  	   429	  
	   194	  	  184	  	  176	  	  260	  	  230	  	   215	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concentration of ATP. Samples were incubated in a water bath at 37°C for 10 minutes 
and 10 µL of each reaction was spotted onto P81 phosphocellulose paper. To terminate 
the reaction and remove any remaining 32P-γATP that may not have been incorporated, 
the spotted P81 paper was washed 4 times in 10 mL of 1% phosphoric acid solution, once 
in 10 mL of ethanol, and set aside to dry under a heat lamp for 5-10 minutes. Dried P81 
paper was exposed to a phosphorimaging screen (Amersham Biosciences) for one hour 
and analyzed using a Storm phosphorimager (Storm 860 Molecular Imager) to detect the 
level of 32P-labelled substrate bound to the P81 paper. The amount of 32P incorporated 
onto the RRRDDDSDDD peptide is directly proportional to the catalytic activity of 
CK2α.  
 
2.4.3 -  Recovery of CK2 activity following treatment with CX-4945 
To determine the ability of the GST- CK2α mutants to restore CK2 activity 
following treatment with increasing concentrations of CX-4945 (final reaction 
concentrations of 10, 20, 30, 40, and 50 nM CX-4945), kinase activity assays were 
performed. Reaction mixtures (final volume 20 µL) were prepared by the addition of 4 
µL of 5X kinase reaction buffer (50 mM Tris buffer, pH 7.5, 100 mM NaCl, 12 mM 
MgCl2, plus [γ-32P] ATP (1 µL per 100 µL of reaction buffer)), 2 µL of 0.1 mM 
RRRDDDSDDD peptide (a CK2 substrate), and 10 µM cold ATP. The appropriate 
amount of ddH2O was added to bring the reaction volume up to 16 µL. In a separate set 
of eppendorf tubes, each purified kinase was then preincubated with either no inhibitor 
(DMSO), or increasing concentrations of CX-4945 (5x the final reaction concentration) 
for 20 minutes in order to saturate the kinase with inhibitor. To start the kinase reaction, 
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180-260 ng of the appropriate preincubated kinase was added to the reaction mixture at 
15-second intervals in order to examine the recovery of CK2 activity at each 
concentration of inhibitor (final volume 20 µL, therefore inhibitor concentrations diluted 
from 5x to 1x and are now at the final reaction concentration of 10, 20, 30, 40, and 50 nM 
CX-4945). Samples were incubated in a water bath at 37°C for 10 minutes and 10 µL of 
each reaction was spotted onto P81 phosphocellulose paper. To halt the reaction and 
remove any remaining 32P-γATP that may not have been incorporated, the spotted P81 
paper was washed 4 times in 10 mL of 1% phosphoric acid solution, once in 10 mL of 
ethanol, and set aside to dry under a heat lamp for 5-10 minutes. Dried P81 paper was 
exposed to a phosphorimaging screen (Amersham Biosciences) for one hour and 
analyzed using a Storm phosphorimager (Storm 860 Molecular Imager) to detect the level 
of 32P-labelled substrate bound to the P81 paper. Samples containing CX-4945 were 
compared to the no inhibitor DMSO control in order to calculate the percent (%) relative 
activity that was restored. 
 
2.5 – Antibodies  
The monoclonal antibody directed against the HA-epitope, biotinylated 3F10 
(Roche), was prepared as previously described28. In order to detect the endogenous and 
exogenous expression of CK2α simultaneously, a polyclonal antibody raised against a 
GST-fusion protein containing the last 51 residues in the C-terminal region of CK2α’ (299-
350) was used (BabCO, Berkley, CA). Due to the sequence similarity between CK2α and 
CK2α’, the GST-fusion antibody can recognize and bind both CK2 isoforms, however, 
the signal is typically more prominent for CK2α’. Phosphospecific antibodies were used 
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to recognize and bind the phosphorylated species of the known CK2 substrates, EIF2β 
(pS 2) and CK2β (pS 2/3/4/8). Monoclonal anti-GAPDH antibody was used as an 
indicator of protein loading. Goat-anti-rabbit (GAR) and goat-anti-mouse (GAM) 
secondary antibodies conjugated to fluorophores detectable at 680 nm and 800 nm 
wavelengths were purchased from (LiCOR, Mandel) to enable detection on the LiCOR 
Odyssey infrared scanner. Similarly, monoclonal streptavidin anti-biotin (SAV) 
secondary antibody conjugated to fluorophore detectable at 680 nm wavelengths was 
purchased from (LiCOR, Mandel).  
 
2.6 – Development of Flp-In™ U2OS cell lines  
  Human osteosarcoma (U2OS) cells containing the Flp-In™ integration site were 
generously provided by Dr. Karmella Haynes (Arizona State University). The vector 
(pcDNA5) that contains identical integration sites required for insertion of the gene of 
interest into the host cells, as well as the Flp-recombinase capable of enabling insertion 
were purchased (Invitrogen). Flp-In™ U2OS cell lines expressing CK2α-HA or CK2α 
(V66A/H160D/I174A)-HA were generated according to the Flp-In™ T-REx™ manual 
provided by Invitrogen98. 
 
2.7 – Cell culture: Maintenance, protein induction, and harvest 
U2OS cells were maintained in Dulbecco’s modified Eagle’s medium (Corning) 
supplemented with 10% fetal bovine serum (FBS – Cansera) and 1% 
penicillin/streptomycin (Invitrogen), at 37°C in an environment also containing 5% CO2. 
The cells were also maintained with 100 µg/mL hygromycin B as a selective pressure in 
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order to maintain the population containing the gene of interest. It is also recommended 
that the confluence of cells within any dish remain above 50%. Since the Flp-In™ 
expression system is TET-on102, the induction of CK2α-HA and CK2α 
(V66A/H160D/I174A)-HA protein expression requires the addition of tetracycline. To 
accomplish this, cells were plated to a confluence of 70-80% 12 hours prior to the point 
of protein induction. Following the 12 hours, the media was aspirated, the cells were 
washed 4x with PBS, and the cells were replenished with fresh medium containing 1 
µg/mL of tetracycline in order to induce protein expression. The cells were then left at 
37°C in an atmosphere containing 5% CO2 for 24 hours. Following expression of CK2α-
HA and CK2α (V66A/H160D/I174A)-HA for 24 hours, the media was again removed, 
the cells were washed 4x with PBS, and the cells were replenished with fresh medium 
again containing 1 µg/mL of tetracycline to maintain expression, as well as 10, 20, 30, 
40, and 50 µM CX-4945 to inhibit CK2. The cells were then again left at 37°C in an 
atmosphere containing 5% CO2 for an additional 24 hours. Following the 24 hour 
incubation with increasing concentrations of CX-4945, the cells were harvested in 
Nonidet P-40 (NP-40) lysis buffer (50 mM Tris-Cl pH 7.5, 150 mM NaCl, 1% NP-40, 
filter sterilized) supplemented with various protease and phosphatase inhibitors (protease 
inhibitors: 1 mM PMSF, 7 µg/mL PepA, 20 µg/mL leupeptin, and 2.9 µg/mL aprotinin - 
phosphatase inhibitors: 1 µM okadaic acid, 1 µM microcystin, 5 mM sodium fluoride, 
and 1 mM sodium orthovanadate). Cell lysates were cleared by centrifugation at 2000 x g 
at 4°C for 20 minutes to remove cell debris. Cell lysates were then stored at -20°C. A 
diagram illustrating the Flp-In™ system for the expression of CK2α-HA and CK2α 
(V66A/H160D/I174A)-HA can be seen in Figure 5. 
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2.8 – SDS-PAGE and Western blotting 
 To determine protein concentration of each lysate to be processed, the BCA 
protein assay103 (Pierce) was utilized. Samples were then prepared for the separation of 
proteins via sodium dodecyl sulphate (SDS) polyacrylamide electrophoresis (SDS-
PAGE) using the method of Laemmli104 by adding an equal volume (relative to the 
volume of each sample) of 2X Laemmli sample buffer (4% SDS, 20% glycerol, 120 mM 
Tris-HCl pH 6.8, and 10% β-mercaptoethanol). Each sample was then heated at 100°C 
for three minutes. Gels were run in SDS-PAGE buffer (192 mM glycine, 25 mM Tris-
base pH 8.0, 0.1% SDS) at 120V for 1.5 hours using the mini-protean II electrophoresis 
cassettes (Biorad). A BLUeye prestained protein ladder (FroggaBio) was utilized in order 
to provide a reference of molecular weight. 
 Following completion of SDS-PAGE, proteins were transferred to a 
polyvinylidene difluoride (PVDF) membrane (Thermo Fisher) using a wet mini trans-
blot® electrophoretic transfer cell105 (Biorad) for 1 hour at 100V in blotting buffer (20% 
methanol, 10 mM Tris-base pH 8.6, 767 mM glycine, and ddH2O). Membranes were then 
blocked with LI-COR blocking solution (LI-COR) for 1 hour and subsequently washed 
three times with tris buffered saline (200 mM Tris-HCl. 500 mM NaCl, pH 7.5) (TBS) 
with 0.1% Tween 20 (TBST). Expression of CK2α-HA and CK2α 
(V66A/H160D/I174A)-HA were detected by incubating the membranes with a 
biotinylated anti-HA antibody (3F10) diluted 1:1000 into 3% bovine-serum albumin 
(BSA)/PBST for 1 hour at room temperature. The membranes were subsequently washed 
three times with PBST and then incubated with a biotin sensitive-streptavidin secondary 
antibody conjugated to a fluorophore capable of being detected at 680 nm (SAV680) for 
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1 hour at room temperature. To detect the CK2-dependent phosphorylation of the 
substrate, EIF2β, membranes were incubated with an antibody (EIF2β P S2) capable of 
recognizing and binding the phosphorylated serine 2 residue in the translation factor 
EIF2β. This antibody was diluted 1:10000 into 3% BSA/TBST and membranes were 
incubated for 1 hour and room temperature. Next, the membranes were washed three 
times with TBST and incubated with a goat-anti-rabbit secondary antibody conjugated to 
a fluorophore capable of being detected at 800 nm (GAR800) for 1 hour at room 
temperature. The antibody (CK2β (P  S2/S3/S4/S8)) sensitive to the CK2-dependent 
phosphorylation of CK2β at up to 4 different serine residues (S2, S3, S4, and S8) was 
diluted 1:10000 into 3% BSA/TBST and membranes were incubated for 1 hour at room 
temperature. Membranes were washed three times with TBST and then were incubated 
with the GAR800 secondary antibody. An anti-GAPDH antibody was used to specifically 
serve as a protein loading control, and was diluted 1:2000 into 3% BSA/TBST and 
membranes were incubated for 1 hour and room temperature. Membranes were 
subsequently washed three times with TBST and then subjected to incubation with the 
GAR800 secondary antibody. Immunocomplexes were visualized using the LiCOR 
odyssey infrared imaging system (LiCOR).  
 
 
 
 
 
 
	  	  
48	  
 
 
 
 
 
Figure 5. Illustration of tetracycline-inducible CK2α-HA and CK2α 
(V66A/H160D/I174A)-HA protein expression in Flp-In U2OS cells 
Adapted from the Flp-In™ T-REx™ manual98 is an illustration of the tetracycline-
inducible protein expression of CK2α-HA and CK2α (V66A/H160D/I174A)-HA. A gene 
encoding resistance for the selective marker, hygromycin b, is located downstream of a 
SV40 promoter that enables selection to maintain the population of cells containing the 
gene of interest (CK2α-HA or CK2α (V66A/H160D/I174A)-HA). In the absence of 
tetracycline (Tet), a Tet-repressor protein (TetR – represented by open black circles) will 
be bound to the Tet-operator (TetO) sequence, thereby suppressing the expression of GOI 
(CK2α-HA or CK2α (V66A/H160D/I174A)-HA). Following the addition of the 
appropriate concentration of tetracycline (represented by the black triangles), the Tet-
repressor protein will become fully bound and the suppression of CK2α-HA or CK2α 
(V66A/H160D/I174A)-HA protein expression will be relieved leading to the expression 
of the respective proteins.  
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2.9 – Immunofluorescence  	    Cells were grown in 6-well dishes on coverslips in DMEM medium containing 1 
µg/mL of tetracycline at 37°C in an atmosphere containing 5% CO2 for 24 hours to 
induce CK2α-HA and CK2α (V66A/H160D/I174A)-HA protein expression. Following 
the 24-hour incubation, medium was aspirated and the cells were fixed in a 10% formalin 
solution in PBS for 15 minutes. The membranes of the cells were then permeabilized for 
10 minutes with 0.1% Triton-X 100 in PBS and non-specific binding was blocked using 
3% BSA/PBS for 1 hour at room temperature. To detect the expression of CK2α-HA and 
CK2α (V66A/H160D/I174A)-HA, the coverslips were incubated with a monoclonal anti-
HA primary antibody directly conjugated to a FITC-Alexa488 fluorophore (Invitrogen) 
diluted 1:1000 in 3% BSA/PBS for 16-18 hours at 4°C. Cell nuclei were stained with 1 
µg/mL Hoechst 33258 (Molecular Probes) for 1 minute. Coverslips were then mounted 
onto glass slides using Antifade Mounting Medium (Thermo Scientific) and protein 
expression was visually detected under a Nikon Eclipse fluorescent microscope. 
Coverslips were washed thoroughly (4 or 5 times) with PBS between each step.  
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3. Results 
3.1 – In vitro kinase assays 
3.1.1 Examining the effect of CK2α mutations on activity 
Site-directed mutagenesis via PCR was used to generate the N-terminally GST-
tagged CK2α mutants containing amino acid substitutions H115L or H160D alone, as 
well as in combination with the previously described double mutant, CK2α-
V66A/I174A77,106,107. To start, I wanted to determine whether these newly incorporated 
mutations into the active site of protein kinase CK2α influenced its activity, and to 
address this question, in vitro kinase assays were performed. From previous studies, the 
Km of ATP for the wild type isoform of CK2α was determined to be approximately 12 
µM108. The kinase assays revealed that the activities of CK2α-WT, as well as the CK2α-
H115L and CK2α-H160D single mutants, were not dramatically different from these 
reports, as I calculated a Km of 13.3 µM, 9.9 µM, and 7.8 µM respectively (Figure 6, 
compare CK2α-WT, CK2α-H115L, and CK2α-H160D). In contrast, it was clear that all 
mutants of CK2α bearing the V66A and I174A amino-acid substitutions displayed a 
reduction in their rate of activity (Figure 6, compare CK2α-V66A/I174, CK2α-
V66A/H115L/I174A, and CK2α-V66A/H160D/I174A). Following non-linear regression, 
it was apparent that there was an increase in the Km, as I calculated Km values of 31.9 
µM, 25.1 µM, and 18.6 µM respectively. Most importantly, it was clear that all GST-
tagged active-site mutants of CK2α retained their ability to phosphorylate an optimized 
CK2 peptide26,109 (RRRDDDSDDD), and therefore no mutations completely abolished 
activity. Collectively, these data suggest that CK2α can tolerate the introduction of 
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additional mutations (H115L or H160D) alone or in combination with V66A/I174A, and 
therefore enabling the investigation of their effects on the sensitivity of CK2 to CX-4945. 
 
3.1.2 – Determining the effect of CK2α mutations on the Ki of CX-4945 
Following our investigation into the effect of amino acid substitutions (H115L, 
H160D, V66A/I174A, V66A/H115L/I174A, and V66A/H160D/I174A) on the activity of 
CK2α, the next step was to perform an evaluation on their ability to effect the inhibition 
of CK2 by CX-4945. To achieve this, I continued the characterization using in vitro 
kinase assays to test various concentrations of ATP against increasing concentrations of 
CX-4945 (1-10 nM) (Figure 7A-F). To quantify this effect, non-linear regression was 
performed to calculate the constant (Ki) for the kinase-inhibitor complex (Figure 7G). I 
detected a tight binding model for the GST-tagged CK2α-WT isoform, as I calculated a 
Ki of 0.3 nM (Figure 7A). In terms of our CK2α isoforms bearing amino acid 
substitution, I observed that CK2α (H115L)was the most sensitive to inhibition by CX-
4945, with a corresponding Ki value of 2.1 nM, followed by the H160D single mutant 
with a Ki value of 2.7 nM (Compare Figure 7B and 7C). This result was not surprising, as 
residues V66 and I174 were not altered in those isoforms. These observations are 
pertinent since structural studies have highlighted V66 and I174 as key hydrophobic 
residues that not only form the small binding pocket of CK2α, but are also critical in the 
binding of small molecule inhibitors25,77,92. In comparison, I was able to detect a notable 
increase in the Ki with the CK2α-V66A/I174A mutant, calculating a Ki of 3.9 nM 
(Figure 7D). Next, amino acid substitutions H115L and H160D 
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Figure 6. Rate (v) (pMol/min) of phosphorylation at various concentrations of ATP 
Phosphorylation studies using [γ-32P] ATP and optimal CK2 peptide RRRDDDSDDD.  
The different forms of CK2 are labeled as follows: GST- CK2α (Blue), GST- CK2α 
H115L (Green), GST- CK2α H160D (Red), GST- CK2α V66A/I174A (dotted Black), 
GST- CK2α V66A/H115L/I174A (dotted Green), and GST- CK2α V66A/H160D/I174A 
(dotted Red). Error bars represent the variation that can be observed between replicate 
assays. The experiment was performed in triplicate (n=3) and each reaction was assayed 
in triplicate 
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were combined with the previously characterized double mutant (V66A/I174A) to 
generate inhibitor-refractory triple mutants of CK2α. I observed the greatest increase in 
the ability to overcome inhibition by CX-4945 with the CK2α triple mutant 
(V66A/H160D/I174A), as I calculated a Ki of 7.4 nM (Compare Figure 7D and 7F). 
Pairing the H115L mutation with V66A and I174A (CK2α-V66A/H115L/I174A) also led 
to an increase in Ki of CX-4945 (Ki= 4.8). 
 
3.1.3 – Assessing the ability of CK2α mutants to overcome inhibition by CX-4945 
  I continued the in vitro evaluation of the CK2α mutants by assessing the ability of 
the CK2α mutants to overcome inhibition by CX-4945 utilizing an enzyme reactivation 
strategy as previously described110. The expectation was that this strategy would enable 
the effective inhibition of wild type CK2α in order to improve the likelihood that 
meaningful difference would be detected between wild type and mutants of CK2α. 
 In fact, measuring kinase activity following the preincubation of wild type CK2α 
with CX-4945 demonstrated that its activity was effectively inhibited (Figure 8 – GST- 
CK2α). In comparison to the DMSO control, which represents the activity of the kinase 
in the absence of inhibitor, I observed a 10, 5, 5, 3, and 3 percent recovery (%) in wild 
type CK2 activity following treatment with 10, 20, 30, 40, and 50 nM CX-4945 
respectively. Subsequently, I wanted to interrogate each mutant of CK2α to identify the 
mutant that best resists the effects by CX-4945. As a result of our in vitro studies 
investigating the changes in Ki following treatment with CX-4945, I hypothesized 
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Figure 7. Effect of CK2α mutants on the inhibition of CK2 by CX-4945  
A) Phosphorylation studies using [γ-32P] ATP and optimal CK2 peptide RRRDDDSDDD 
were performed to assess the ability of the CK2α mutants to overcome inhibition by CX-
4945. B) The effect of the various mutants on the inhibition of CK2 was quantified using 
non-linear regression (Graphpad Prism 6) to determine the inhibitor constant (Ki). Error 
bars represent the variation that can be observed between replicate assays. The 
experiment was performed in triplicate (n=3) and each reaction was assayed in triplicate. 
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that similar trends would be observed, indicating that the single mutants are inferior to 
the double mutant, and the triple mutants are superior to the double mutant. In fact, our 
observations indicate that the CK2α-H115L single mutant was the least capable of 
overcoming inhibition by CX-4945, as I calculated a 15, 7, 6, 4, and 4 percent recovery 
(%) relative to its DMSO control. The performance of the CK2α-H160D single mutant 
was only marginally superior, as I observed a percent recovery (%) of 25, 9, 7, 6, and 5. 
Assessment of the CK2α-V66A/I174A double mutant confirmed that it could outperform 
the single mutants, as I attained a 31, 16, 13, 10, and 7 percent reactivation (%) of CK2α 
activity. In comparison, combining the single mutations with the CK2α-V66A/I174A 
double mutant to generate the inhibitor-refractory triple mutants, CK2α-
V66A/H115L/I174A and CK2α-V66A/H160D/I174A, I was able to increase the recovery 
of CK2α activity beyond the previously established double mutant of CK2α. More 
specifically, the CK2α-V66A/H160D/I174A mutant accomplished the greatest restoration 
of CK2α activity, with a percent reactivation (%) of 50, 29, 24, 16, and 17 following 
treatment with 10, 20, 30, 40, and 50 nM of CX-4945 respectively. The CK2α mutant 
bearing V66A, H115L, and I174A amino acid substitutions appeared to be 
indistinguishable from the double mutant, with a 31, 20, 14, 9, and 7 percent reactivation 
(%) of CK2α activity.  
Collectively, these data have indicated that manipulation of the active site of 
protein kinase CK2α has generated mutants with reduced sensitivity to inhibition by the 
CK2 inhibitor, CX-4945. In particular, the mutant that was least sensitive to inhibition 
contained a new combination of amino-acid substitutions (V66A/H160D/I174A) that has 
not been previously examined.. To extend these findings beyond studies using purified 
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components, my next objective is to develop inducible cell lines expressing CK2α-WT, , 
or CK2α-V66A/H160D/I174A. 
 
3.2 Characterizing the induction of CK2α-HA and CK2α (V66A/H160D/I174A)-HA in 
Flp-In U2OS cell lines 
In order to investigate CK2 in cells, I generated tetracycline-inducible stable cell 
lines expressing the wild type (CK2α-HA), as well as a triple mutant (CK2α 
(V66A/H160D/I174A)-HA) form of the CK2α catalytic subunit without expression of the 
regulatory CK2β subunit. Although previous studies in the Litchfield lab have illustrated 
that optimal expression and stability of CK2α is achieved in the presence of the 
regulatory subunit, CK2β, I utilized Flp-In™ T-REx™ expression technology, which 
currently does not support a bidirectional system as previously described28,98,111. The 
advantage of Flp-In™ technology is its targeted approach, as Flp-In™ host cells and 
donor constructs contain a specific integration site such that the gene of interest can only 
be incorporated into a specific location within the genome98. To achieve titratable 
expression, CK2α (wild-type and triple mutant) was transfected into Flp-In™ U20S cells 
(generously provided by Dr. Karmella Haynes) that already contain an integration site 
and stably express a tetracycline transactivator fusion protein. The epitope tag (HA) fused 
to the C-terminus of each CK2α construct (Figure 5) allowed for the detection of 
exogenously expressed CK2α in the presence of endogenous CK2. Because the 
generation of stable cells expressing protein kinase CK2α in the Flp-In™ T-REx™ 
background had not previously 
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Figure 8. Measuring the ability of CK2α mutants to overcome inhibition by CX-
4945. An enzyme reactivation strategy was utilized in order to assess the ability of the 
CK2α mutants to overcome inhibition by CX-4945. The different forms of CK2 are 
indicated in the legend within the Figure. Error bars represent the variation that can be 
observed between replicate assays. The experiment was performed in triplicate (n=3) and 
each reaction was also assayed in triplicate. 
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been accomplished, I began with a detailed characterization to ensure I could achieve 
robust and equal expression of CK2α across cells lines. 
To start, each cell line (CK2α-HA and CK2α (V66A/H160D/I174A)-HA) was 
cultured in the presence of increasing concentrations of tetracycline for 24 hours to 
examine modulation of CK2α expression. As demonstrated in Fig. 9 (A-B), western blot 
analysis using a HA-3F10 (anti-HA) antibody yielded the presence of three distinct 
bands. Of particular importance, is the band located at the expected molecular mass (48 
kDa) for HA-tagged CK2α, as this band increased in size with increasing concentration 
of tetracycline111. The remaining two bands with molecular weights of approximately 75 
kDa and 125 kDa were deemed non-specific. I detected basal levels of expression in the 
absence of tetracycline in both cell lines, indicating a degree of leakiness within the 
pCMV promoter controlling expression. Furthermore, expression of wild type and triple 
mutant CK2α in Flp-In U20S cells was comparable to basal levels when cultured in the 
presence of tetracycline concentrations up to 10 ng/mL. Following the addition of 100, 
1000 or 1500 ng/mL of tetracycline, a large increase in the level of expression detected 
with 3F10 anti-HA antibodies can be observed. In particular, culturing cells in the 
presence of 1000 or 1500 ng/mL of tetracycline achieved the highest level of expression, 
as a dramatic difference can be observed between 100 ng/mL and 1000 or 1500 ng/mL. 
In contrast, no dramatic difference was observed between the levels of expression 
attained with 1000 or 1500 ng/mL of tetracycline (Appendix, Figure 15). Importantly, it 
is also worth noting that no dramatic difference in expression between cell lines 
expressing CK2α-HA or CK2α (V66A/H160D/I174A)-HA were observed.  
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Subsequently, I wanted to examine the time course of induction following the addition of 
tetracycline to determine when expression is detectable and reaches saturation. To 
accomplish this, expression was induced with 1000 ng/mL of tetracycline, and cells were 
harvested following 3, 6, 12, 24, and 48-hours of treatment. Under these conditions, 
expression of both cell lines was detectable as early as 3 hours and reached saturation at 
24 hours (Figure 9. C-D). More specifically, I was able to reach a modest level of 
induction following 3 and 6 hours in the presence of 1000 ng/mL tetracycline, generating 
approximately a 5 and 10-fold increase in protein expression respectively, relative to 
basal levels in the absence of tetracycline. As I extended the exposure of the cell lines to 
1000 ng/mL of tetracycline for 12, 24, and 48 hours, I observed an increase in the level of 
protein expression. In comparison to the cell lines in the absence of tetracycline, I 
calculated a 15-fold increase in protein expression following 12, 24 and 48 hours. Again, 
no dramatic difference was observed between cell lines, suggesting equal ability to 
respond to the presence of tetracycline in a time-dependent manner (Appendix, Figure 15 
for quantifications).  
Next, I was interested in comparing the expression levels of the exogenous 
relative to endogenous CK2α in our Flp-In U2OS cell lines. To detect both exogenously 
and endogenously expressed CK2α simultaneously, I used an antibody raised against the 
last 51 residues in the C-terminus of CK2α’299-350. Due to the 90% sequence similarity 
existing between CK2α and CK2α’, I am also able to detect the presence of CK2α 
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Figure 9. Inducible expression of CK2α in Flp-In U2OS cell lines 
A-B) Flp-In U2OS cells (expressing CK2α-HA (A) or CK2α (V66A/H160D/I174A)-HA 
(B)) were cultured in the absence (0 ng/mL) or presence of increasing concentrations of 
tetracycline (1-1500 ng/mL) for 24 hours. C-D) Flp-In U2OS cells (expressing CK2α-HA 
(C) or CK2α (V66A/H160D/I174A)-HA (D)) were cultured in the presence of 1 µg/mL 
of tetracycline for increasing time intervals (0-48 hours). Protein expression was 
examined using Western blots and an Anti-HA antibody. The positions of the HA-tagged 
CK2α subunits are indicated and their respective molecular weights are marked. 
Nonspecific protein species that are detectable using the Anti-HA antibody are also 
indicated. An antibody used to detect the presence of GAPDH served as an indicator of 
protein loading (n=2).  
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Figure 10. Comparing expression levels of endogenous and exogenous CK2α in Flp-
In U2OS cell lines. Flp-In U2OS cell (expressing CK2α-HA (A) or CK2α 
(V66A/H160D/I174A)-HA (B)) were cultured in the presence of 1µg/mL of tetracycline 
and harvested at increasing time intervals (0-48 hours). Protein expression was assessed 
using Western blots and a GST-fusion antibody capable of detecting endogenous and 
exogenous CK2α species simultaneously. The positions of the exogenous HA-tagged and 
endogenous CK2α subunits have been designated and their molecular weights have been 
marked. An antibody used to detect the presence of GAPDH served as an indicator of 
protein loading (n=2).  
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As demonstrated in Figure 10 (A-B), both cell lines are capable of achieving levels of 
exogenous expression below or equal, but not greater than, the endogenous levels of 
CK2α depending on the length of induction with 1000 ng/mL of tetracycline. More 
specifically, for both cell lines I detected levels of exogenously expressed CK2α below 
those of the endogenous CK2α following 6 and 12 hours of induction. In comparison, I 
observed that similar proportions (1:1) of exogenous to endogenous CK2α when cells 
were induced in the presence of 1000 ng/mL of tetracycline for 24 or 48 hours could be 
achieved. 
Lastly, I wanted to determine if the majority of the population of cells were 
expressing the genes of interest (CK2α-HA) and (CK2α (V66A/H160D/I174A)-HA). To 
validate this, I performed (with help from Edward Cruise) immunofluorescence utilizing 
an antibody that could recognize and bind to the HA-epitope located on the C-terminus of 
the wild type (CK2α-HA) and triple mutant (CK2α (V66A/H160D/I174A)-HA) kinase, 
which was directly conjugated to a FITC-labeled secondary antibody for visual detection. 
As shown in Figure 11 (A-B), Flp-In U2OS cell lines demonstrate a relatively high 
homogeneity for the expression of both wild type and triple mutant CK2α. Additionally, 
it was apparent that the majority of cells stained with the FITC-conjugated primary 
antibody are also present with the Hoechst 33342 nuclear stain, suggesting that the 
majority of cells have incorporated the gene of interest. It was apparent however, that the 
intensity of the immunofluorescence varied from cell to cell, although it is possible that 
this is a product of the synchronicity of the cells as well as the amount of tetracycline that 
is transported into each cells.  
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Altogether, dose response and time-course evaluations have served to demonstrate 
that I have successfully created stable cell-lines with the rapid, abundant, and tightly 
regulated expression of wild type and triple mutant CK2α (CK2α-HA and CK2α 
(V66A/H160D/I174A)-HA). Importantly, similar levels of endogenous and exogenous 
CK2α within the Flp-In U2OS can be achieved. It was also illustrated that I have 
generated cell lines with a large proportion of cells expressing CK2α-HA or CK2α 
(V66A/H160D/I174A)-HA. Therefore, because I have identified the conditions at which I 
can achieve the optimal expression of CK2α-HA and CK2α (V66A/H160D/I174A)-HA, I 
can now proceed to investigating the effect of their expression on the ability of CX-4945 
to inhibit CK2. However, I first need to examine the conditions at which the inhibition of 
endogenous CK2 within our Flp-In U2OS cell lines can be detected. 	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Figure 11. Indirect immunofluorescent detection of expressed CK2α-HA and CK2α 
(V66A/H160D/I174A)-HA in Flp-In U2OS cell lines. Flp-In U2OS cells (expressing 
CK2α-HA (A) or CK2α (V66A/H160D/I174A)-HA (B)) were cultured in the absence (-) 
or presence (+) of 1 µg/mL of tetracycline for 24 hours. The cells were then fixed and 
stained with a FITC-conjugated Anti-HA monoclonal antibody as previously described in 
the materials and methods. Cells were also stained with a Hoechst 33258 DAPI stain in 
order to visualize cell nuclei. A phase contrast image has also been included. Identical 
fields were imaged in the absence (-) or presence (+) of tetracycline for both cell lines (A-
B)(n=3). 	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3.3 Dose-response and time-course evaluation of CX-4945 on Flp-In U2OS cells 
Having demonstrated that expression of the CK2a V66A/H160D/I174A mutant 
could be achieved in cells, I was next interested in testing whether expression of this 
mutant could render cells less sensitive to CX-4945.  As a prelude to these experiments, I 
characterized the effects of CX-4945 on the Flp-In USOS cells. I employed dose-
response and time-course experiments to profile the effects of increasing concentrations 
(1 nm – 50 µM) of CX-4945 on the activity of endogenous CK2 at various time points (1 
– 24 hours). To monitor the inhibition of CK2 activity in cells, the Litchfield lab has 
generated an antibody that recognizes a phosphorylated serine residue located at position 
2 in EIF2β (P S2), which has been characterized as a CK2-specific phosphorylation 
site112–114. Under the conditions used in this experiment paired with western-blot 
methodology, I was able to detect a reduction in EIF2β (p S2) as early as 8 hours (Figure 
12). In respects to the objective of this experiment, I observed the greatest reduction in 
the EIF2β (p S2) signal following treatment of Flp-In U2OS cells with 10 – 50 µM CX-
4945 for 24 hours. Overall, these data suggest that I can most effectively eliminate the 
EIF2β (p S2) signal, indicating inhibition of endogenous CK2α, following treatment of 
Flp-In U2OS cells with CX-4945 for 24 hours. 
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Figure 12. Effect of CX-4945 on Flp-In U2OS cells in the absence of tetracycline 
Flp-In U2OS cells were cultured in the absence (-) of tetracycline and were treated with 
increasing concentrations of CX-4945 (0-50 µM). Cells were then harvested at various 
time points as indicated and CK2α activity was analyzed via Western blots. The 
phosphospecific EIF2β (p S2) antibody described in the materials and methods was used 
to probe for the activity of CK2α (n=1).  
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3.4	  –	  Effect	  of	  CK2α	  (V66A/H160D/I174A)-­‐HA	  on	  the	  inhibition	  of	  CK2	  by	  CX-­‐
4945	  	  
Having demonstrated that I could most effectively inhibit the activity of 
endogenous CK2 following treatment of cell lines with CX-4945 for 24 hours, I now 
wanted to test the effects of expressing the CK2α triple mutant on CX-4945. Since it has 
been previously illustrated that the expression of inhibitor-refractory mutants can be used 
as a tool for the study of protein kinases86,87,115, the implications of this study are 
significant. If successful, this may provide new opportunities in order to distinguish 
cellular functions between the various isoforms of CK2 and may set the stage for the 
thorough evaluation of its inhibitors. Therefore, to fulfill this objective, I will induce the 
expression of the CK2α (V66A/H160D/I174A)-HA triple mutant in the Flp-In U2OS cell 
line to determine its ability to refract the effects of CX-4945. 
Demonstrated in Figure 13 (A-B, - Tet samples), in the absence of tetracycline I 
observed a reduction in EIF2β (P S2) following treatment with 10 µM CX-4945 for 24 
hours. The EIF2β (P S2) signal was completely eliminated at concentrations of 20-50 µM 
CX-4945. After the addition of tetracycline to induce the expression of the wild type 
kinase (CK2α-HA), I observed a weak ability to recover the loss of EIF2β (P S2) (Figure 
13A, + Tet samples). Quantified in Figure 14A, induction of CK2α-HA in Flp-In U2OS 
cells treated with 10 µM CX-4945 for 24 hours yielded a 12% recovery of EIF2β (P S2). 
At concentrations beyond 10 µM, restoration of phosphorylated EIF2β (P S2) was 
unattainable. Subsequently, I assessed the novel triple mutant (CK2α 
(V66A/H160D/I174A)-HA) and discovered a considerable recovery of EIF2β (P S2) 
following the induction of protein expression (Figure 13B, + Tet samples). Relative to its 
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DMSO control, I calculated an 82 %, 43 %, 18 %, 11%, and 3 % recovery in EIF2β (P 
S2) at inhibitor concentrations of 10, 20, 30, 40, and 50 µM respectively (Figure 14B, + 
Tet samples). 
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Figure 13. Testing the effect of the CK2α (V66A/H160D/I174A)-HA triple mutant on 
CX-4945 in Flp-In U2OS cells. Flp-In U2OS cells (expressing CK2α-HA (A) or CK2α 
(V66A/H160D/I174A)-HA (B)) were cultured in the absence (-) or presence (+) of 1 
µg/mL of tetracycline for 24 hours. Cells were then treated for an additional 24 hours 
with DMSO or increasing concentrations of CX-4945 (10-50 µM). Cells were harvested 
and 10 µg of each cell lysate was subjected to SDS-PAGE and Western blotting to assess 
CK2α protein expression and inhibition. The expression of the HA-tagged CK2α subunits 
was detected using an Anti-HA antibody and the inhibition of CK2α was monitored using 
the phosphospecific EIF2β (p S2) antibody as indicated. An antibody capable of detecting 
GAPDH was used as an indicator of sample loading. (n=3). 	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Figure 14. Quantifying the effect of expressing CK2α-HA and CK2α 
(V66A/H160D/I174A)-HA on CX-4945. The effect of expressing CK2α-HA (A) and 
CK2α (V66A/H160D/I174A)-HA (B) on inhibition of CK2 by CX-4945 was determined 
by quantifying the signal intensity of the CK2-specific phosphorylation of EIF2β (P S2) 
using Odyssey software. The calculated EIF2β (P S2) signal for each cell lysate was 
compared to its GAPDH signal (EIF2β (P S2)/GAPDH signal ratio) in order to normalize 
for any differences in protein loading. Error bars represent the variation that can be 
observed between replicate cell lysates (n=3). Cell lysates in the absence of tetracycline 
are indicated in solid black and cell lysates in the presence of tetracycline are indicated in 
checkered or striped black (n=3).  
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4. Discussion 
4.1 Mutational analysis of CK2α mutants 
4.1.1 – Effect of CK2α mutations on catalytic activity 
Previous studies have shown that the manipulation of residues within key 
conserved regions of protein kinases can influence their catalytic activity2. Although this 
study was focusing on residues necessary for the binding of CX-4945 into the active site 
of CK2α, it was important to ensure that the ability of CK2 to bind and utilize ATP was 
not jeopardized. Using assay conditions previously established in the Litchfield lab for 
measuring the activity of GST-tagged protein kinase CK2116 it was shown that the active 
site mutants of CK2α were highly comparable, with the exception of the CK2α mutants 
bearing V66A/I174A, V66A/H115L/I174A, or V66A/H160D/I174A amino acid 
substitutions. Most importantly, it was demonstrated that all isoforms of CK2α retained 
their ability to phosphorylate a specific substrate (RRRDDDSDDD109). 
Studies originally describing the key structural determinants restricting access to 
the active site of CK2 allowing small molecule inhibitors to bind tightly have generated 
similar mutations92 (V66A/I174A). They demonstrated that the activity of the CK2α 
(V66A/I174A) double mutant was indistinguishable from wild-type CK2α. In contrast, I 
observed a minor reduction in activity in all mutants bearing the V66A and I174A amino 
acid substitutions. However, due to the inconsistency to the observations made in the 
previous study92, it remains inconclusive if these mutations truly have a negative impact 
on activity. It is reasonable to consider that the substitution of residues, V66 and I174, to 
a smaller amino acid such as alanine, does not allow ATP to remain appropriately 
positioned within the active site of CK2. Although it has been identified that lysine 68 
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(K68) is the residue necessary for ATP binding28, altering the structure of the active site 
may still have an effect on the docking of ATP, as well as the alignment of the gamma (γ) 
phosphate with the hydroxyl group of the acceptor substrate. Presumably, this would 
result in a diminished rate at which the mutated kinase can phosphorylate a recipient 
substrate. However, more work is required to understand the effect of the V66A and 
I174A mutations on the activity of CK2  
As a whole, amino-acid substitutions (H115L, H160D, V66A/I174A, 
V66A/H115L/I174A, and V66A/H160D/I174A) in the active site of CK2α did not impair 
the overall ability of CK2α to bind and utilize ATP to transfer the γ-phosphate group to 
an acceptor substrate (RRRDDDSDDD). I conclude that the minor loss in activity is not 
significant for achieving our objectives, as I can normalize the activity of all kinases 
when performing future experiments. Therefore, I moved forward to address the issue of 
how these mutations will effect the inhibition of CK2 by CX-4945.  
 
4.1.2 – Examining the effect of CK2α mutations on CX-4945 
It has been well documented that CX-4945 – the inhibitor of protein kinase CK2 
that is of interest in the current study – behaves in an ATP-competitive manner117,118. As 
a result, I believed that I could model this competition in order to determine if the newly 
introduced amino-acid substitutions could alter the ability of CX-4945 to inhibit CK2α, 
which would be reflected by a change in Ki. Furthermore, if these mutations do impair 
the ability of CX-4945 to inhibit CK2α, then following preincubation with CX-4945 in 
order to saturate the active site with inhibitor, I should detect more CK2α activity in 
comparison to the wild type kinase. Presumably, this is because the inhibitor will be less 
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able to remain bound within the active site of our mutants. In fact, the current study 
reported for the first time the ability of various inhibitor-refractory mutants of CK2α to 
affect the inhibitory properties of CX-4945. In particular, I identified a new combination 
of amino-acid substitutions (V66A/H160D/I174A) that was considerably less sensitive to 
inhibition by CX-4945, and consequently can restore more specific activity in 
comparison to the previously established double mutant (V66A/I174A). 	  
With the exception of the V66A/I174A double mutant, the CK2α mutants 
generated in the present study have not been previously examined for their ability to 
attenuate the effects of CX-4945, and there are a few important observations that should 
be mentioned. Notably, the GST-CK2α mutants containing single amino-acid 
substitutions, H115L or H160D, demonstrated that they do have the capacity to weaken 
the effects of CX-4945. This is a noteworthy contribution to the field because it suggests 
that these particular mutations may alter the internal structure of the active site of CK2α, 
or abolish interactions that may help to keep the inhibitor engaged within the active site. 
It was apparent however, that the single mutants were unable to outperform the GST-
CK2α mutant containing the previously established amino-acid substitutions, V66A and 
I174A. It is possible that this result is simply due to the fact that two mutations may be 
better than one, creating more structural changes that lessen the ability of CX-4945 to 
bind the active of CK2α beyond what is attainable with a single mutation. Although, it is 
more likely that the observed differences between the single and double mutants were 
due to the reported function of the V66 and I174 residues. It has previously been 
demonstrated that residues V66 and I174 are necessary for the binding of inhibitors to 
CK2α, since they contribute key energy for binding and function as a clamp to stabilize 
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the inhibitor compound within the active site of CK2α106. Therefore, it may not be 
surprising that the mutants bearing single amino-acid substitutions (H115L and H160D) 
were more sensitive to inhibition by CX-4945, presumably because I maintained the 
existence of these critical residues (V66 and I174). 
Interestingly, in a study performed by Battistutta R, et al31 (2011) investigating 
the affect of the V66A and I174A mutations on the IC50 of CX-4945, only a moderate 
increase was observed when these substitutions were examined individually. In contrast, 
when combined to form the CK2α-V66A/I174A double mutant, they detected a 
significant increase in the IC50 of CX-4945 (15-fold). This finding was intriguing, as it 
suggests that certain combinations of amino-acid substitutions may have an additive 
effect on the ability of CK2α to resist inhibition by CX-4945. Because I have shown that 
the CK2α single mutants still display the capacity to impair the inhibition by CX-4945 
and restore kinase activity in the presence of CX-4945, I hypothesized that I would 
observe an additive effect if I combined H115L or H160D with the previously established 
double mutant. Our results (section 4.1.2) provided support for the hypothesis that 
combination of these residues has an additive effect. Significantly, this served as the first 
time triple mutants of CK2α have exhibited an amplified ability to alter the inhibition of 
CX-4945, therefore recovering more activity in the presence of inhibitor than what was 
previously attainable31. The advantage to the development of such mutants is that I 
increase the range in which I might detect a recovery in the specific activity of CK2α. 
Additionally, this finding is noteworthy as the creation of protein kinases that are 
insensitive to inhibition hold major implications for the elucidation of their specific 
cellular roles, as well as the validation of their viability as a potential therapeutic target 
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(Discussed in detail in section 4.5 – Implications of inhibitor-insensitive mutants of 
protein kinase CK2).  
In conclusion, I have determined that residues H115 and H160 are important for 
the inhibition of CK2α by CX-4945. More specifically, I have demonstrated that the 
replacement of these residues, in particular H160, to residues found within the majority 
of the remaining protein kinases, resulted in a considerable loss in sensitivity to 
inhibition. I do acknowledge however, that in no instance was the loss of CK2α activity 
fully restored, and therefore additional work may be warranted. To address these 
concerns, identification of additional residues that may be necessary for the binding of 
inhibitors to the active site of CK2α should be pursued. In addition, optimal stability and 
activity of protein kinase CK2 has been observed in the presence of the CK2β regulatory 
subunit. Therefore, future studies should consider combining CK2β with the CK2α-
V66A/H160D/I174A triple mutant to determine if the level of activity restored following 
treatment with CX-4945 can be improved. Despite the limitations, I believe that the 
generation of cell lines that readily express mutants with a reduced sensitivity to 
inhibition will provide a platform for the investigation of CK2’s roles within cells, as 
well as the in-cell evaluation of current CK2 inhibitors.  
 
4.2	  –	  Inducible	  expression	  of	  CK2α	  in	  Flp-­‐In	  U2OS	  cells	  
Previous explorations into the expression of the various protein kinase CK2 
subunits within cells have primarily relied on methods of transient transfection78,119–121. 
Even though we can often achieve robust expression via methods that introduce DNA 
transiently, there are several disadvantages that may hinder our ability to obtain 
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reproducible data122. Since the DNA is not incorporated into the genome of the host cell 
and therefore will not be replicated, expression of the transfected DNA is short-lived and 
will typically be diluted out of the population through cell division and common 
passaging of the cells122. This will require the need to reintroduce the DNA of interest 
and can result in an increase in the variability observed between experiments, because 
achieving consistent efficiency through various methods of transfection has proven to be 
challenging122. In addition to their short-lived nature, there is no way to control the 
transcriptional and translational machinery of the host cell, thereby eliminating the ability 
to regulate the expression of your gene of interest. To overcome these limitations, the 
Litchfield lab has shifted its focus into the development of tetracycline-inducible stable 
cell lines expressing various forms of protein kinase CK228,30,123,124. Therefore, I decided 
to further expand our repertoire of inducible cell lines by introducing CK2α-HA, as well 
as the novel CK2α (V66A/H160D/I174A)-HA triple mutant into Flp-In™ U2OS cells 
using the recently developed Flp-In™ T-Rex™ recombination technology98. 
 Briefly, Flp-In™ T-Rex™ recombination technology requires the use of the Flp 
recombinase125–127 originally derived from the 2 um plasmid of Saccharomyces cerevisiae 
to insert fragments of DNA between short flippase recognition target (FRT) sites in host 
cells also containing a tetracycline-responsive element98. Following the generation of a 
host cell line containing a tetracycline-responsive element, as well as integrated FRT 
sites, the ability to introduce a gene of interest becomes very rapid and efficient. 
Furthermore, due to the site-specific integration of DNA into the genome of the host cell, 
Flp-In™ T-Rex™ cell lines are isogenic and consequently protein expression is equal 
across a population of cells98,128. This allows for polyclonal selection of stably expressing 
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cell lines rather than the isolation of individual colonies, which significantly reduces the 
overall time invested into the development of cell lines.  
 Interested in a cell-based system to achieve stable integration of a gene of interest, 
Milligan et al (2011) took advantage of the Flp-In™ T-Rex™ system to regulate the 
expression of various G protein-coupled receptors129 (GPCR). Immunofluorescent 
analysis demonstrated that robust expression of the inducible GPCR cell lines was only 
attainable in the presence of doxycycline, although a faint detection of protein expression 
in the absence of doxycycline was also observed. Subsequently, they performed western-
blot analysis to characterize the time it takes to detect expression following treatment 
with doxycycline. They were able to detect the expression of the human muscarinic M3 
GPCR as early as 6 hours, and expression was fully saturated after 14 hours of treatment 
with 0.5 μg/mL doxycycline. In addition, Dr. Karmella Haynes (who generously 
provided us with Flp-In™ T-REx™ U2OS cells) has also utilized this technology to 
introduce various modular synthetic transcriptional factors (pc-TFs) into HEK293 and 
U2OS cells128. Briefly highlighted in the characterization of their Flp-In U2OS cell 
lines128, western blot analysis detected robust expression in the majority of cell lines 
following the addition of 1 μg/mL doxycycline. In light of the evidence provided above, 
I obtained the U2OS cells engineered by Haynes laboratory to introduce constructs 
encoding CK2 through integration via the Flp-In™ T-Rex™ recombination strategy98, 
with the expectation that these cells rapid, robust, and regulated protein expression. 
In general, our observations were highly comparable to those made in the 
previous studies mentioned above due to the universal nature of the Flp-In™ T-Rex™ 
system. However, there are some differences that should be noted. First, I was able to 
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detect changes in protein expression at earlier (3-6 hour) and later (12-24 hour) time 
points following treatment of the Flp-In U2OS cell lines with tetracycline. It was also 
demonstrated that I could achieve these differences over a broader range of tetracycline 
concentrations. However, this could simply be attributed to the conditions used when 
monitoring protein expression (different epitope tags that require the use of different 
antibodies for detection). Second, I observed faint protein expression in both Flp-In 
U2OS cell lines when in the absence of tetracycline indicating some leakiness with the 
promoter controlling transcription on the gene of interest, which has previously observed 
with tet-on systems102,130–132. It is plausible that sources of DMEM and FBS routinely 
used in cell culture contain traces of tetracycline. For this reason, all sources of media 
and FBS should be thoroughly examined for the presence of tetracycline, as an extra 
purification step could be performed to minimize the likelihood of observing leaky 
expression. Despite this minor limitation, on the whole, our results are in high 
concordance to what has previously been attainable using the Flp-In™ T-REx™ 
recombination technology. Importantly, I achieved our objective of creating cell lines 
capable of the rapid, robust, and inducible expression of CK2α-HA and CK2α 
(V66A/H160D/I174A)-HA.  
 Also worth noting, is the fact that I was able to achieve robust and stable 
expression of CK2α-HA and CK2α (V66A/H160D/I174A)-HA in the absence of the 
CK2β regulatory subunit. Although it has been observed that the catalytic CK2 subunits 
(α and α’) can exist and be active in the absence of CK2β52,119,120, earlier studies 
describing the expression of epitope-tagged isoforms of CK2 could only detect optimal 
expression and stability of the catalytic subunits when in the presence of CK2β119. As a 
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reminder, Flp-In™ T-REx™ technology currently permits the introduction of only a 
single gene of interest, and does not support a bidirectional system that would be required 
to coordinately express both catalytic and regulatory subunits of CK228,133. This is an 
intriguing result and therefore will warrant further investigation. To evaluate the capacity 
of the exogenous CK2α subunits to form complexes with endogenous CK2β, 
immunoprecipitation studies should be performed on all Flp-In™ T-REx™ U2OS cell 
lines following induction of protein expression. The HA-3F10 antibody that recognizes 
the HA-epitope on the C-terminus of the wild type and mutant CK2α could be used to 
perform immunoprecipitations with immunoblots performed to detect the presence of 
CK2β. Detection of CK2β would indicate that a complex is being formed between the 
exogenously expressed CK2α and the endogenous CK2β of the Flp-In™ T-REx™ 
U2OS host cells, providing explanation for the ability of both cell lines to achieve, rapid, 
robust, stable and regulated expression of CK2. 
 Overall, I demonstrated that I have successfully generated a cell line that can 
rapidly and robustly wild type and mutant forms of CK2α under the control of 
tetracycline. More specifically, I was able to achieve robust protein expression that 
remained stable in the absence of a requirement for increased expression of the regulatory 
CK2β subunit. It is envisaged that these cell lines will be extremely advantageous for 
experiments investigating the specific roles of CK2α in cellular systems, as well as 
providing a platform for the evaluation of Ck2 inhibitors.  The implications and 
advantages of having inducible cell lines expressing inhibitor-resistant mutants of protein 
kinase CK2 will be discussed in more detail (Section 4.5 – Implications of inhibitor-
insensitive mutants of protein kinase CK2). 
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4.3 Dose-response and time-course evaluation of CX-4945 on Flp-In U2OS cells 
The selection of an appropriate biomarker is important when attempting to monitor 
the cellular activity of a protein kinase. Previous studies treating mammalian cells with 
CX-4945 have been able to observe the rapid inhibition of CK2 by monitoring its activity 
through the detection of its phosphorylated substrate, Akt. For example, studies 
investigating the use of MEK inhibitors to overcome resistance to CX-4945, as well as 
the preclinical characterization of CX-4945 in PC3 prostate carcinoma cells, 
demonstrated a rapid reduction in the CK2-specific phosphorylation of Akt (P-Akt S129) 
following treatment with 1 -10 µM CX-4945 for only 2-4 hours74,134. In some respects, 
these findings are not surprising, considering the role that CK2 has been shown to play in 
cellular processes such as proliferation and survival27,35,52. However, previous experience 
in the Litchfield lab has suggested that Akt is not a reliable indicator of CK2 activity 
(Appendix, Figure 16). In fact, it was demonstrated that rapid and dynamic responses to 
the inhibition of CK2 following treatment of HeLa and UTA6 cells with CX-4945 were 
detected using an antibody capable of recognizing the CK2-specific phosphorylation of 
EIF2β at serine 129 (P-EIF2β S2). As a result, I selected this substrate to serve as our 
biomarker to monitor the activity of CK2 in the Flp-In U2OS cell lines. Using this 
antibody (P-EIF2β S2), I demonstrated that I could most effectively inhibit the activity of 
endogenous CK2 following treatment of Flp-In U2OS cells with 25-50 µM CX-4945 for 
24 hours. It is important to recognize however, that there is a possibility that these results 
may be confounded as a result of the prolonged exposure of the Flp-In U2OS cells to CX-
4945 since it has been documented that inhibitors such as CX-4945 are not strictly 
selective to protein kinase CK2, and may target other serine/threonine protein kinases 
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including the PIM and DYRK families135. Despite the limitation, these studies revealed 
that inhibition of EIF2β (P S2) could be achieved using CX-4945 setting the stage for 
investigation of its effects on the Flp-In U2OS cell expressing wild type and the 
(V66A/H160D/I174A) triple mutant of CK2α. 
 
4.4 – Testing the effects of the CK2α (V66A/H160D/I174A) triple mutant on the 
cellular response of CX-4945 
The development of mutants that are less sensitive to inhibition can serve an 
instrumental purpose for the study of protein kinases. For example, the establishment of a 
system in which the target kinase is noticeably less sensitive to inhibition may allow for 
the identification of its protein substrates, which in turn can provide valuable information 
about the functions that are coordinated by the kinases within cells. Furthermore, mutants 
that are less sensitive to inhibitors may enable the establishment of experimental systems 
for evaluation of the effects of various inhibitors on their anticipated target. Therefore, 
since our in vitro data (refer to sections) indicated that the triple mutant of CK2α 
(V66A/H160D/I174A) is notably less sensitive to inhibition by CX-4945, I generated 
tetracycline-inducible cell lines (Flp-In U2OS) to determine how the expression of this 
mutant would effect the cellular response of CX-4945.  
In the present study, I demonstrated that the expression of the CK2α 
V66A/H160D/I174A-HA triple mutant led to a considerable recovery of the CK2-
specific phosphorylation of EIF2β (p S2) following treatment of Flp-In U2OS cells in the 
presence of 10 µM CX-4945 for 24 hours. Although there was a restoration in the loss of 
phosphorylated EIF2β (p S2), it is evident that phosphorylation was not completely 
	  	  
93	  
restored. A potential explanation for this result is that EIF2β may serve as an indicator of 
CK2 holoenzyme activity. In fact, it has been reported that the CK2-specific 
phosphorylation of EIF2β (p S2) requires the presence of both the catalytic (α) and 
regulatory (β) subunits112,113. As previously noted, the Flp-In recombination technology 
does not currently support a dual-expression system. Consequently, to determine if the 
addition of CK2β will improve the ability of the triple mutant to resist the effects of CX-
4945, it would be necessary to transiently transfect CK2β into the Flp-In U2OS cell lines 
expressing the CK2α triple mutant. If successful, then perhaps the development of a dual-
expression system capable of utilizing Flp-In recombination technology would be 
beneficial.  
Despite the limitation that EIF2β (P S2) may not be the most appropriate biomarker 
for the activity of CK2α, I believe that I have now established a system that provides new 
opportunities in order to identify cellular substrates of CK2α, especially those substrates 
that do not require the presence of the regulatory CK2β subunit. This is especially 
important because of the complexity of protein kinase CK2. I have previously mentioned 
that various forms of CK2 can exist within cells, each displaying the potential to exhibit 
functions that are independent from one another. In addition, it remains poorly 
understood whether inhibitors of CK2 display uniform effects against the various forms 
of CK2 or if they have the ability to better target one isoform over another. Therefore, the 
identification of biomarkers that can serve to monitor the activity of specific CK2 
isoforms will be very useful in order to expand our knowledge regarding the functions of 
protein kinase CK2, as well as the effects of its inhibitors.  
	  	  
94	  
In summary, the CK2α (V66A/H160D/I174A) triple mutant may provide valuable 
insight regarding the cellular behavior of CK2α when in the absence of the CK2β 
regulatory subunit. However, the creation of cell lines expressing inhibitor-insensitive 
mutants of the remaining isoforms of CK2 would enable us to conduct a more thorough 
investigation, which may serve to better elucidate the intricacies of CK2. 
 
4.5 – Implications of inhibitor-refractory mutants of protein kinase CK2 
The development of mutants that display a reduced sensitivity to inhibition can 
serve an invaluable purpose in the study of protein kinase86,87. Importantly, the current 
study has demonstrated that I have created a mutant of protein kinase CK2 (CK2α 
(V66A/H160D/I174A)-HA) that is noticeably less sensitive to inhibition by the CK2 
inhibitor, CX-4945. Therefore, I believe that our study has now provided us with a 
unique advantage that may help elucidate many unknowns regarding protein kinase CK2, 
which may have previously been unattainable.  
 
4.5.1 - Functional compensation vs. specialization 
As a result of the recent surge in excitement surrounding protein kinase CK2, 
there is now ample evidence providing insight into the plethora of functions that CK2 
may be responsible for orchestrating within cells. However, the precise form of CK2 
responsible for its catalytic activity often remains poorly understood due to the 
complexity of the kinase (two catalytic subunits, CK2α and CK2α’, that can be active 
with or without the regulatory subunit, CK2β). Consequently, I believe that the 
generation of the CK2α (V66A/H160D/I174A)-HA triple mutant provides new 
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opportunities to distinguish the catalytic activity exhibited by CK2α and CK2α’. The 
separation of their catalytic activity will enable us to more thoroughly examine cellular 
functions of protein kinase CK2, and more specifically, help distinguish functions that 
may be compensatory from those that may be isoform-specific. However, this will 
eventually require the generation of a mutant of CK2α’ that is also less sensitive to 
inhibition by CX-4945, although this may be relatively straightforward considering the 
structural similarity to its CK2α counterpart.  
 
4.5.2 - Evaluation of current and novel inhibitors of protein kinase CK2 
Another challenge that has recently emerged involves the development of 
inhibitors for the therapeutic targeting of CK2. Due to its increasing implications in 
human disease, in particular cancer, the number of compounds developed to inhibit CK2 
has radically increased. As previously mentioned, the majority of these compounds have 
only been examined in vitro, and even when they exhibit cellular effects it often remains 
unknown whether the observed effects are a result of CK2 inhibition. Following the 
induction of the CK2α (V66A/H160D/I174A)-HA triple mutant, the Flp-In U2OS cells 
can be treated with CK2 inhibitors. Using a biomarker (P-EIF2β S2) in order to 
specifically monitor the activity of CK2, we can then assess if the observed effects are a 
result of the specific inhibition of CK2. This will be reflected by the ability of the CK2α 
(V66A/H160D/I174A)-HA triple mutant to restore the phosphorylation of EIF2β. 
Importantly, I believe that the present study has now provided us with a unique 
opportunity that may help validate the specificity of current and novel inhibitors of CK2 
in cells, which has previously been a challenge.  
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4.6 – Future directions 
The generation of the CK2α (V66A/H160D/I174A)-HA triple mutant has provided us 
with a significant advantage in order to investigate protein kinase CK2 in ways that have 
previously been unattainable. It is envisaged that the creation of such mutants may enable 
identification of biomarkers that can serve to monitor the activity of a specific form of 
CK2. We may then be able to distinguish the catalytic activity exhibited by CK2α or 
CK2α’ in the absence and presence of the regulatory subunit, CK2β. As a result, this may 
enable us to more precisely evaluate the functions of discreet forms of CK2 in cells. The 
creation of inhibitor-insensitive mutants of CK2 will also provide a foundation for a 
thorough evaluation of its inhibitors. More specifically, it will be possible to examine the 
ability of CK2 inhibitors to target one particular isoform over another, which may help to 
elucidate information that could dramatically improve the therapeutic targeting of CK2 in 
cancer. Overall, I believe that the generation of the CK2α (V66A/H160D/I174A) triple 
mutant provides evidence supporting the feasibility of creating inhibitor-insensitive 
mutants of CK2.  
Perhaps the most noteworthy outcome of the present study was the ability of the 
CK2α (V66A/H160D/I174A) triple mutant to affect the ability of CX-4945 to inhibit 
CK2 in Flp-In U2OS cells. However, it is also a great accomplishment that I was able to 
achieve rapid, robust, and stable expression of the CK2α triple mutant in the absence of 
the regulatory subunit, CK2β. As previously mentioned, the current understanding is that 
both catalytic subunits (CK2α and CK2α’) require the regulatory CK2β subunit in order 
to reach their optimal expression and stability111. Immunoprecipitation analysis would be 
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an important complement to the current study, as it would allow us to determine if the 
exogenously expressed CK2α-HA and CK2α (V66A/H160D/I174A)-HA can form 
complexes with CK2β. If not, then I have established a unique opportunity in order to 
identify a biomarker that can serve to monitor the activity of CK2α, in the absence of the 
regulatory CK2β subunit. This could be accomplished through the use of more advanced 
techniques such as mass spectroscopy (MS), which permits the ability to monitor 
hundreds to thousands of peptides or phosphopeptides simultaneously136. Employing a 
technique that has revolutionized the scale at which we can quantify proteins in cells will 
empower us to perform a global analysis of the phosphoproteome. This will enable us to 
access the consequence of inhibiting the activity of CK2α on the phosphorylation 
landscape of cellular proteins. Subsequently, we could perform a parallel experiment 
following the expression of our CK2α (V66A/H160D/I174A) triple mutant in order to 
identify those proteins whose phosphorylation is restored. Any protein whose 
phosphorylation is restored would classify that protein as cellular substrate of CK2α, 
since its loss of phosphorylation was a direct result of the specific inhibition of CK2α. 
Importantly, this may provide valuable insight regarding the cellular behavior of CK2α 
when in the absence of the CK2β regulatory subunit. 
Although this study has demonstrated that we have achieved significant advances, we 
currently have only generated an inhibitor-insensitive mutant for the CK2α catalytic 
subunit. Therefore, the creation of a mutant of CK2α’ that is also noticeably less sensitive 
to inhibition by CX-4945 would be a logical continuation to the present study. Due to its 
structural resemblance, as well as its high sequence similarity, the generation of a mutant 
of CK2α’ should be readily attainable. In fact, CK2α’ contains the same hydrophobic 
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residues (V67 and I175 in CK2α’), as well as the histidine residue (H161 in CK2α’) that 
were mutated in order to create the CK2α triple mutant in the present study. Additionally, 
the establishment of a bidirectional expression vector capable of integration via Flp-In™ 
T-REx™ recombination technology should be pursued.  
 
4.7 – General summary 
The main objective of the present study was to create a mutant of CK2α that could 
impair the ability of CX-4945 to inhibit CK2 in cells. In order to achieve this objective 
our study was broken down into two parts – the rationale design, purification and in vitro 
analysis to determine which CK2α mutant displayed the greatest reduction in sensitivity 
to inhibition, followed by the generation of a tetracycline-inducible cell line in order to 
achieve its regulated expression in cells. The in vitro analysis lead to the discovery of a 
CK2α triple mutant, namely CK2α (V66A/H160D/I174), that was less sensitive to 
inhibition in comparison to the previously established V66A/I174A double mutant. As a 
result, I generated a cell line using Flp-In™ T-REx™ technology, and showed that I 
could achieve the rapid, robust, and stable expression of the CK2α triple mutant under 
tight regulation by tetracycline. This was achieved in the absence of the regulatory 
subunit, CK2β, which may be an unexpected observation considering previous studies 
have suggested that optimal expression and stability requires interaction with CK2β. 
Most importantly, I illustrated that expression of the CK2α triple mutant in Flp-In U2OS 
cells could influence the ability of CX-4945 to inhibit CK2. I acknowledge that the 
selected biomarker (P-EIF2β S2) may not have been ideal for monitoring the activity of 
the CK2α catalytic subunit alone since previous studies have demonstrated that EIF2β is 
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selectively phosphorylated by the CK2 holoenzyme112,113. Nevertheless, I have now 
established a system that will allow us to pursue the identification of substrates that will 
better serve as indicators of CK2α catalytic activity in the absence of CK2β.  
Given that previous studies have revealed several cellular processes involving CK2, 
as well as providing information concerning its inhibition by various inhibitors, many 
new questions and avenues can now be explored. Accordingly, I believe that the present 
study has established a solid platform in which future work can be conducted. In this 
respect, the development of the CK2α (V66A/H160D/I174A) triple mutant that is 
considerably less sensitive to inhibition by CX-4945 will serve an instrumental purpose 
in order to broaden our understanding regarding the cellular functions of CK2, as well as 
its inhibition by specific inhibitors. 
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5	  -­‐	  Appendix	  	  
Figure	  15.	  Quantification	  of	  protein	  expression	  in	  Flp-­‐In	  U2OS	  cell	  lines	  (A-­‐B)	  CK2α-­‐HA.	  (C-­‐D)	  CK2α	  (V66A/H160D/I174A)-­‐HA.	  	  	  	  
	  	  	  	  	  	  
A) B) 
C) D) 
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Figure	  16.	  Characterization	  of	  CK2-­‐phosphorylation	  specific	  antibodies	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Sample	  calculation	  Calculating	  specific	  activity	  (GST-­‐CK2α)	  All	  reactions	  were	  performed	  in	  triplicate	  and	  an	  average	  was	  taken,	  this	  represents	  a	  single	  reaction.	  	  [GST-­‐CK2α]=	  6.06	  mg/mL	  2	  μL	  of	  GST-­‐CK2α	  (6.06	  μg/μL)	  was	  initially	  diluted	  into	  250	  μL	  of	  CK2	  dilution	  buffer	  	  	  Therefore,	  (2	  μL)*	  (6.06	  μg/μL)=	  12.12	  μg	  of	  GST-­‐CK2α	  	  Next,	  4	  μL	  of	  the	  250	  μL	  sample	  was	  taken	  in	  order	  to	  start	  the	  kinase	  reaction	  	  Therefore,	  (12.12	  μg)*(4	  μL/	  250	  μL)=	  0.193	  μg	  	  	  The	  reaction	  proceeded	  for	  10	  minutes	  	  10	  μL	  of	  the	  total	  kinase	  reaction	  (20	  μL	  final	  volume)	  was	  then	  spotted	  onto	  P81	  paper	  	  Therefore,	  (0.193	  μg)/2	  =	  0.0969	  μg	  of	  GST-­‐CK2α	  	  	  The	  10-­‐minute	  reaction	  (GST-­‐CK2α	  phosphorylating	  a	  RRRDDDSDDD	  peptide)	  yielded	  a	  count	  (CPM)	  of	  859749.14, and the spotted standards yielded a CPM of 
82236698.38 
 
Therefore, to calculate the CPM/pMol of ATP in the standard – (82236698.38 CPM) /(10 
µL spot * 100 µM ATP * 5 for the dilution)= 16447 CPM/pMol  
 
 
Therefore, to calculate the specific activity of GST-CK2α: 
 
(8597491.4 CPM) / (16447 CPM/pMol)= 522.7 pMol of ATP incorporated onto the 
RRRDDDSDDD peptide 
 
(522.7 pMol) / (10 minutes)= 52.27 pMol/min 
 
(52.27 pMol/min) / (0.0000969 mg) = 539422.1 pMol/min/mg of GST-CK2α 
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